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1. INTRODUCTION;(1,2) 
                              The drug administration from oral route have wide acceptance up to 50-
60% of total dosage forms. The solid dosage forms are popular because of ease of 
administration, accurate dosage, self-medication, pain avoidance and most importantly the 
patient compliance. The most popular solid dosage forms are being tablets and capsules; one 
important drawback of this dosage forms for the some patients, is difficulty to swallow. Drinking 
water plays an important role in the swallowing of oral dosage forms. Often times people 
experience inconvenience in swallowing conventional dosage forms such as tablet when water is 
not available, in the case of the motion sickness (kinetosis) and sudden episodes of coughing 
during the common cold, allergic condition and bronchitis. For these reason, tablets that can 
rapidly dissolve or disintegrate in the oral cavity have attracted a great deal of attention. 
Orodispersible tablets are not only indicated for people who have swallowing difficulties, but 
also are ideal for active people. 
                            Oral dispersible tablets are also called as mouth-dissolving tablets, melt-in 
mouth tablets, fast dissolving tablets, rapimelts, porous tablets, quick dissolving etc. Oral 
dispersible tablets are those when put on tongue disintegrate instantaneously releasing the drug 
which dissolve or disperses in the saliva. The faster the drug into solution, quicker the absorption 
and onset of clinical effect. Some drugs are absorbed from the mouth, pharynx and esophagus as 
the saliva passes down into the stomach. In such cases, the bioavailability of drug is significantly 
greater than those observed from conventional tablets dosage form. The advantage of oral 
dissolving dosage forms are increasingly being recognized in both, industry and academics. 
Their growing importance was underlined recently when European pharmacopoeia adopted the 
term “ Orodispersible tablet” as a tablet that to be placed in the mouth where it disperses rapidly 
before swallowing. 
                              According to European pharmacopoeia, the ODT should 
disperse/disintegrate in less than three minutes. The basic approach in development of ODT is 
the use of superdisintegrants like cross linked carboxymethyl cellulose (croscarmellose), 
cellactose80, sodium starch glycolate (primogel, explotab), polyvinylpyrollidone (polyplasdone) 
etc, which provide instantaneous disintegration of tablet after putting on tongue, their by release 
the drug in saliva.  
                                                                                                    INTRODUCTION 
 
DEPARTMENT OF PHARMACEUTICS, NCP, ERODE Page 2 
 
                           The bioavailability of some drugs may be increased due to absorption of drug in 
oral cavity and also due to pregastric absorption of saliva containing dispersed drugs that pass 
down into the stomach. More ever, the amount of drug that is subjected to first pass metabolism 
is reduced as compared to standard tablet. The technologies used for manufacturing of the oral 
dispersing tablets are freeze-drying, spray-drying, tablet moulding, sublimation, sugar-based 
excipients, tablet compression and disintegration addition. As a result of increased life 
expectancy, the elderly constitute a large portion of the worldwide population today. These 
people eventually will experience deterioration of their physiological and physical abilities. 
                              Recent developments in technology have presented viable alternatives for the 
patients who may have difficulty in swallowing tablets or liquids. Traditional tablets and 
capsules administered with an 8-oz, the glass of water may be inconvenient or impractical for 
some patients. For example a very elderly patient may not be able to swallow a daily dose of 
antihistaminic drugs. An eight year old child with allergies could use a more convenient dosage 
form than antihistamine syrup. A schizophrenic patient the institution setting can hide a 
conventional tablet under his or her tongue to avoid their daily of dose of atypical antipsychotic. 
A middle-aged woman undergoing radiation therapy for breast cancer may be too nauseous to 
swallow her h2-blockers. 
                               To overcome these drawbacks, orally dispersible tablets (ODT) or mouth 
dissolving tablet (MDT); has emerged as alternative oral dosage forms. These are novel types, of 
tablets that disintegrate/dissolve/disperse in saliva within few seconds. 
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1.A) TABLETS :
(3)
 
                                  Tablets may be defined as solid pharmaceutical dosage forms containing 
medicament or medicaments with or without suitable recipients & prepared either by 
compression or molding. 
i) Advantages of tablets:
  
Some of the potential advantages of tablets are as follows.
 
 They are the unit dosage form having greatest capabilities amongst all the oral dosage form 
for the dose precision and least content variability. 
 Their cost is lowest amongst all the oral dosage forms. 
 They are lightest and the most compact amongst all the oral dosage form. 
 They are easiest and cheapest for packaging and transportation. 
 They lend themselves to certain special release profile products such as enteric or delayed 
release products. 
 Tablets are better suited to large-scale production than other unit oral dosage forms. 
 They have the best-combined properties of chemical, mechanical, microbiological stability 
amongst all the oral dosage forms. 
ii) Classification of tablets:
 
Based on the route of administration or the function, the tablets are classified as follows.
 
1) Tablets ingested orally. 
 Compressed tablet 
 Multiple compressed tablet              
i) Layered Tablet 
ii) Compression coated Tablet 
 Repeat action Tablet 
 Delayed action and enteric-coated Tablet 
 Sugar and chocolate-coated tablet 
            a) Film coated tablet 
            b) Chewable Tablet 
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2) Tablets used in the oral cavity. 
 Buccal Tablet 
 Sublingual Tablet 
 Troches and Lozenges 
 Dental cones 
3) Tablets administered by other routes. 
 Implantation Tablet 
 Vaginal Tablets 
4) Tablets used to prepare solution. 
 Effervescent Tablet 
 Dispensing Tablet 
 Hypodermic Tablet 
 Tablets Triturates  
iii) Manufacturing Methods 
(3)
 
Tablets are manufactured by Direct compression, Wet granulation or Dry granulation  
method. 
1) Direct Compression: 
                 The term direct compression is used to define the process by which tablets are 
compressed directly from powder blends of active ingredient and suitable excipients, which will 
flow uniformly in the die cavity & forms a firm compact. 
2) Wet Granulation:  
                            Wet granulation is the process in which a liquid is added to a powder in a 
vessel equipped with any type of agitation that will produce agglomeration or granules. These 
granules after drying are compressed to form tablets.  
3) Dry Granulation:       
                 In this technique, there is no use of liquids. The process involves the formation 
of slugs. Then the slugs are screened or milled to produce granules. The granules formed are then 
compressed to form tablets.  
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Table No.1.1: The processing Steps Commonly required in the Various Tablet  
preparation techniques: 
Processing 
steps 
Wet 
Granulation 
Dry 
Granulation 
Direct 
Compression 
Raw materials       
Weight       
Screen       
Mix         - 
Compress (slug)                  -       - 
Wet mass        -     - 
Mill        -     - 
Dry        -     - 
Mill         - 
Mix         - 
Compress 
 
      
 
iv) Advantages of Direct compression   :- 
 This process is more economical. It requires fewer manufacturing steps, less processing 
time & thus reduces labour cost & less process validation. 
 The processing steps required no need of moisture, heat, and high compaction pressure. 
 There is an optimization of tablet disintegration, in which each primary drug particle is 
liberated from the tablet mass & is available for dissolution. 
                           In the present aging society, easy-to-use dosage forms for elderly patient, whose 
swallowing function is often decreased, are in great demand. The use of conventional tablets, 
capsules, and liquid or syrup preparations were not always easy-to-use dosage forms for elderly 
patients because of their decrease motor function. Similarly the use of conventional tablets is 
challenging to paediatric, geriatric, and uncooperative patients who may have difficulty to 
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swallow tablets and is also problematic when water is unavailable or when patients have a 
persistent cough or gag-reflux.
 
                    These problems have been addressed by the recent introduction of Oral dispersible 
tablets(ODT) which also known as  a quick-dissolving tablet (also known as fast-dissolving, fast-
dissolving multiparticulate, rapid-dissolving, mouth-dissolving, fast-melting, fast dispersing 
tablets) is an oral tablets that does not require water for swallowing. The tablets dissolve within 
60 seconds when placed in mouth or in oral cavity. 
 
1.B) ORAL DISPERSIBLE / DISINTEGRATING TABLET
(4)
 
        In recent decades, a variety of pharmaceutical research has been conducted to 
develop new dosage forms. Considering quality of life, most of these efforts have been focused 
on ease of medication. Among the dosage form developed to facilitate ease of medication, the 
oral dispersible tablet is one of the most widely employed commercial products. 
 
 
i) Defination     
                      A oral-dissolving drug delivery system in most cases is a tablet that dissolving or 
disintegrates in the oral cavity without the need of water or chewing. Most oral-dissolving drug 
delivery system films must include substances to mask the taste of the active ingredient. This 
masked active ingredient is then swallowed by the patients saliva along with the soluble and 
insoluble excipients. 
                    These are also called melt-in-mouth, repimelt, porous tablet, fast dissolving, quick 
dissolving or rapid disintegrating tablets. Oral Disintegrating  tablets are also called as Oro-
dispersible tablets, Quick disintegrating tablets , Fast disintegrating tablets, rapid dissolving 
tablets and Rapimelts. 
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                                    A                        B                                C 
Figure 1.1:              A- Disintegration of Oro dispersible tablet after 5 seconds 
                      B- Disintegration of Oro dispersible tablet after 10 seconds 
                      C- Disintegration of Oro dispersible tablet after 15 seconds 
                                 D- Disintegration of Oro dispersible tablet after 20 seconds 
                                 E- Disintegration of Oro dispersible tablet after 25 seconds 
                                 F- Disintegration of Oro dispersible tablet after 30 seconds 
 
Recently, European Pharmacopoeia has used the term Oro-dispersible tablets that 
disperses readily and within 3 min in mouth before swallowing.  
  
United State Food and Drug Administration (FDA) defined Oro-dispersible tablets as, 
“A solid dosage form containing medicinal substance of active ingredient which disintegrates 
usually within a matter of seconds.” 
 
     “Oral dispersible tablets is solid dosage form that contains medicinal substances And that 
disintegrate and dissolve rapidly without water (within seconds) .” 
                             The need for delivering drugs to patients efficiently and with few side effects 
has prompted pharmaceutical companies to engage in the development of the new drug delivery 
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systems. A solid dosage form that dissolves or disintegrates rapidly in oral  cavity, resulting in 
solution or suspension without the need of water is known as oral dispersing dosage form or oral 
dissolving tablets. When this type of tablet is gone into the stomach, the 0.1N HCL will serve to 
rapidly dissolve the tablet.  
                          Many patients find it difficult to swallow tablets and hard gelatin capsules and 
do not take their medicines as prescribed. The target populations for these new oral-
dissolving/disintegrating dosage forms have generally been pediatric, geriatric, bedridden or 
developmentally disabled patients., who are traveling or who have little or no access of water are 
also good candidates for oral dissolving / disintegrating tablets. Other groups that may 
experience problems using conventional oral dosage form include the mentally ill, 
developmentally disable and patients who are uncooperative. A difficulty in swallowing 
(dysphasia) tablets or capsules is common problem among all age groups, especially in elderly 
and pediatrics. For this reasons, tablets that can dissolve or disintegrate in oral cavity, have 
attracted a great deal of attention. 
                        Indeed, Oral dispersible tablet is an important and attractive alternative to liquid 
dosage form. Syrups are best for pediatrics but they are bulky and drugs are not as stable in 
liquid form as in solid form like tablets.  
                         Oro-dispersible tablets are characterized by high porosity, and low hardness, 
when administered an in-situ suspension is created in the oral cavity as the tablet disintegrates 
and is subsequently swallowed. Some tablets are designed to dissolve in saliva remarkably fast, 
within a few seconds, and are true oral-dissolving tablets. Others contain agents to enhance the 
rate of tablet disintegration in the oral cavity, and are more appropriately termed oral-
disintegrating tablets, as they may take up to a minute to completely disintegrate. When put on 
tongue, this tablet disintegrates instantaneously, releasing the drug, which dissolves or disperses 
in the saliva. Some drugs are absorbed from the mouth, pharynx and oesophagus as the saliva 
passes down into the stomach. In such cases, bioavailability of drug is significantly greater than 
those observed from conventional tablet dosage form. the disintegration time of these tablets 
depend largely on size and hardness parameters. 
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ii) Criteria for Oral dispersible Drug Delivery System
 (2)
 
 
 
 The tablets should not require water to swallow, but it should dissolve or disintegrate in 
the mouth in matter of seconds. 
 Be compatible with taste masking. 
 Be portable without fragility concern. 
 Have a pleasant the mouth feel. 
 Leave minimum or no residue in  mouth after oral administration. 
 Exhibit low sensitive to environmental condition as temperature and humidity. 
 Allow the manufacture of the tablet using conventional processing and packaging 
 Equipments at low cost. 
iii) Requirements of oral dispersible tablets; 
An ideal ODT should 
 Require no water for oral administration, yet dissolving/disperse/disintegrate in a matter 
of seconds. 
 Be harder and less friable. 
 Leave minimal or on residue in mouth after administration. 
 Exhibit low sensitivity to environment condition (temperature and humidity). 
 Allow the manufacture of tablet by using conventional processing and packing 
equipment. 
iv)  Advantages of ODT; 
 Ease of administration to patient who refuse to swallow a tablet, such as paediatric, 
geriatric, and psychiatric patient. 
 Convenience of administration and accurate dosing as compared to liquid. 
 No need of water to swallow the dosage form, which is highly convenient feature for 
patient who are travelling and do not have immediate access to water. 
 Good mouth feels property of ODT helps to change the basic view of medication as 
“bitter pill” particularly for paediatric patients. 
 Rapid dissolution of drug and absorption, which may produce rapid, onset of action. 
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 Some drug are absorbed from the mouth and oesophagus as the saliva passes down into 
the stomach in such cases bioavailability of drug is increased. 
 Ability to provide advantage of liquid medication in the form of solid preparation. 
 Pregastric absorption can result in improved bioavailability and as a result of reduced 
dosage, improved bioavailability and as a result of reduced dosage improved clinical 
performance through a reduction of unwanted effect. 
 Achieve increased bioavailability/rapid absorption through pregastric absorption of drug 
from mouth, pharynx and oesophagus as saliva passes down. 
 The risk of chocking or suffocation during oral administration of conventional 
formulation due to physical obstruction is avoided, thus providing improved safety. 
 New business opportunity like product differentiation, product promotion, patent 
extension and life cycle management. 
v) Disadvantages of ODT; 
 The tablets usually have insufficient mechanical strength. Hence, careful handling is 
required. 
 The tablets may leave unpleasant taste and/or grittiness in mouth if not formulated 
Properly. 
 Tablets are very fragile and lack physical resistance. Because the tablets are very porous 
and low compression forces are used to prepare them. They cannot be packed in 
conventional strips or in bottles and special packaging is required. 
 Bitter drugs have to be taste masked by various techniques which in turn increases the 
time  and cost of production. 
                 Their growing importance of oral dispersible tablet was under lined recently when 
European Pharmacopoeia adopted the term “Oro-dispersible Tablet” as a tablet that to be placed 
in the mouth where it disperses rapidly before swallowing
. 
vi)  Salient feature of Oral Dispersible Drug Delivery System; 
 Ease of administration for patients who are mentally ill, disabled and uncooperative.  
 Quick disintegration and dissolution of the dosage form.                                                    
 Overcomes unacceptable taste of the drugs.                                                                                 
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 Can be designed to leave minimal or no residue in the mouth after administration and 
also to provide a pleasant mouth feel.   
 Allows high drug loading.                                                                                                             
 Ability to provide advantages of liquid medication in the form of solid preparation.            
 Adaptable and amenable to existing processing and packaging machinery                          
vii) Possible benefits of orally dispersible drugs. 
1. Clinical: 
 Improved drug absorption. 
 Faster onset of action. 
 Minimized first pass effect. 
 Improved bioavailability. 
2. Medicinal: 
 No tablet or capsule to swallow or chew. 
 Better taste, no water needed. 
 Improved safety and efficacy. 
 Improved compliance. 
3. Technical: 
 More accurate dosing than liquid products. 
 Can use sugars and other excipients that are generally recognized as safe. 
 Improved stability because of unit-dose packaging. 
 Manufactured with common process and conventional equipment. 
4. Business: 
 Lifecycle Management: re-formulation is a strategy to prolong market exclusivity as it 
may delay or reduce generic erosion at patent expiry. 
  Differentiation in a crowded market  
 For generic companies it offer the prospect of superior generic drugs in order to gain 
market dominance upon the expiration of patents 
 Cost effective drug development 
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1.3) Mechanism of tablet disintegrates 
(1)
 
The tablet breaks to primary particles by one or more of the mechanisms listed below:- 
1. Capillary action 
2. Swelling 
3. Because of heat of wetting 
4. Disintegrating particle/particle repulsive forces 
5. Deformation 
6. Release of gases 
         7. Enzymatic action 
1 ) Capillary action  
                               Disintegration by capillary action is always the first step. When we put the 
tablet into suitable aqueous medium, the medium penetrates into the tablet and replaces the air 
adsorbed on the particles, which weakens the intermolecular bond and breaks the tablet into fine 
particles. Water uptake by tablet depends upon hydrophilicity of the drug /excipients and on 
tableting conditions. For these types of disintegrates maintenance of porous structure and low 
interfacial tension towards aqueous fluid is necessary which helps in disintegration by creating a 
hydrophilic network around the drug particles. 
2 ) Swelling:      
                          Perhaps the most widely accepted general mechanism of action for tablet 
disintegration is swelling Tablets with high porosity show poor disintegration due to lack of 
adequate swelling force. On the other hand, sufficient swelling force is exerted in the tablet with 
low porosity. It is worthwhile to note that if the packing fraction is very high, fluid is unable to 
penetrate in the tablet and disintegration is again slows down. 
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                    Fig.no.1.2  :  Disintegration of tablet by wicking and swelling 
3 ) Heat of wetting (air expansion) 
                          When disintegrates with exothermic properties gets wetted, localized stress is 
generated due to capillary air expansion, which helps in disintegration of tablet. This 
explanation, however, is limited to only a few types of disintegrates and cannot describe the 
action of most modern disintegrating agents. 
4. ) Disintegrating particle / particle repulsive forces 
                         Another mechanism of disintegration attempts to explain the swelling of tablet 
made with „non-swellable‟ disintegrates.  Guyot-Hermann has proposed a particle repulsion 
theory based On the observation that non-swelling particle also cause disintegration of tablet. 
The electric Repulsive force between particle are the mechanism of disintegration and water is 
required  for it. Researchers found that repulsion is secondary to wicking. 
5. ) Deformation.  
                   Hess had proved that during tablet compression, disintegrated particles get deformed 
and these deformed particles get into their normal structure when they come in contact with 
aqueous media or water. Occasionally, the swelling capacity of starch was improved when 
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granules were extensively deformed during compression. This increase in size of the deformed 
particles produces a break up of the tablet. 
                           
                         Fig.1. 3. Disintegration by deformation and repulsion
 
6) Release of gases 
                    Carbon dioxide released within tablets on wetting due to interaction between 
bicarbonate and carbonate with citric acid or tartaric acid. The tablet disintegrates due to 
generation of pressure within the tablet. This effervescent mixture is used when pharmacist needs 
to formulate very rapidly dissolving tablets or fast disintegrating tablet. As these disintegrates  
are highly sensitive to small changes  in humidity level and temperature ,strict control of 
environment is required during manufacturing of the tablets .The effervescent blend is either 
added immediately prior to compression or can be added in to two separate fraction of 
formulation. 
7 ) Enzymatic reaction 
                         Here, enzymes presents in the body act as disintegrates. These enzymes destroy 
the binding action of binder and helps in disintegration. 
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                                               Table.1.2. Disintegrating Enzymes. 
ENZYMES BINDER 
Amylase Starch 
Protease Gelatin 
Cellulose Cellulose and its derivatives 
Invertase Sucrose 
 
ix) Fundamentals of oral dispersible tablets: 
                          For rapid dissolution or disintegration of dosage form, water must rapidly 
penetrate into the tablet matrix to cause quick disintegration & instantaneous dissolution of the 
tablet. Several techniques are used to achieve these fundamentals, to formulate mouth-dissolving 
tablet. Some of the techniques are described below. 
1.4) Techniques for Preparing Oral Dispersible Tablets
 (5)
 
                  Many techniques have been reported for the formulation of  Orodispersible tablets. 
1. Freeze drying / lyophilisation 
2. Tablet Moulding 
3. Spray drying 
4. Sublimation 
5. Direct compression 
6. Mass extrusion 
 
1. Freeze-Drying or Lyophilisation 
                                Freeze drying is the process in which water is sublimed from the product 
after it is frozen. This technique creates an amorphous porous structure that can dissolve rapidly. 
A typical procedure involved in the manufacturing of ODT using this technique is mentioned 
here. The active drug is dissolved or dispersed in an aqueous solution of a carrier/polymer. The 
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mixture is done by weight and poured in the walls of the preformed blister packs. The trays 
holding the blister packs are passed through liquid nitrogen freezing tunnel to freeze the drug 
solution or dispersion. Then the frozen blister packs are placed in refrigerated cabinets to 
continue the freeze-drying. After freeze-drying the aluminium foil backing is applied on a 
blister-sealing machine. Finally the blisters are packaged and shipped. The freeze-drying 
technique has demonstrated improved absorption and increase in bioavailability. The major 
disadvantages of lyophilisation technique are that it is expensive and time consuming; fragility 
makes conventional packaging unsuitable for these products and poor stability under stressed 
conditions. 
 
2. Tablet Moulding: 
                            Moulding process is of two types i.e. solvent method and heat method. Solvent 
method involves moistening the powder blend with a hydro alcoholic solvent followed by 
compression at low pressures in moulded plates to form a wetted mass (compression moulding). 
The solvent is then removed by air-drying. The tablets manufactured in this manner are less 
compact than compressed tablets and posses a porous structure that hastens dissolution. The heat 
moulding process involves preparation of a suspension that contains a drug, agar and sugar (e.g. 
mannitol or lactose) and pouring the suspension in the blister packaging wells, solidifying the 
agar at the room temperature to form a jelly and drying at 30○C under vacuum. The mechanical 
strength of moulded tablets is a matter of great concern. Binding agents, which increase the 
mechanical strength of the tablets, need to be incorporated. Taste masking is an added problem 
to this technology. 
                             The taste masked drug particles were prepared by spray congealing a molten 
mixture of hydrogenated cottonseed oil, sodium carbonate, lecithin, polyethylene glycol and an 
active ingredient into a lactose based tablet triturate form. Compared to the lyophilisation 
technique, tablets produced by the moulding technique are easier to scale up for industrial 
manufacture. 
                               In this technology, water-soluble ingredients are used so that tablet 
disintegrate and dissolve rapidly. The powder blend is moistened with a hydro alcoholic solvent 
and is moulded in to tablet using compression pressure lower than used in conventional tablets 
compression. The solvent is then removed by air-drying. Moulded tablets have a porous structure 
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that enhances dissolution. Two problems commonly encountered are mechanical strength and 
poor taste masking characteristics. Using binding agents such as sucrose, acacia or poly vinyl 
pyrrolidone can increase the mechanical strength of the tablet. 
         To overcome poor taste masking characteristic Van Scoik. Incorporated drug 
containing discrete particles, which were formed by spray congealing a molten mixture of 
hydrogenated cottonseed oil, sodium bicarbonate, lecithin, polyethylene glycol and active 
ingredient into a lactose based tablet triturate form. Tablets prepared by this method are solid 
dispersions. Physical form of drug in the tablets depends on whether and to what extent it 
dissolves in the wetted mass. The drug can exist as discrete particles or micro particles in the 
matrix.  Different moulding techniques can be used to prepare mouth-dissolving tablets:  
a. Compression Moulding: The powder mixture previously wetted with a solvent like 
ethanol/water is compressed into mould plates to form a wetted mass.  
b. Heat Moulding: A molten matrix in which drug is dissolved or dispersed can be directly 
moulded into orodispersable Tablets.  
c. No vacuum lyophilization: This process involves evaporation of solvent from a drug solution 
or suspention at a standard pressure.  
        Moulded tablets possess porous structure, which facilitates rapid disintegration and 
easy dissolution. Moulded tablets offer improved taste due to water-soluble sugars present in 
dispersion matrix. But moulded tablets lack good mechanical strength and can undergo breakage 
or erosion during handling and opening of blister packs. However, adding sucrose, acacia or 
polyvinyl pyrrolidone can increase mechanical strength 
3. Spray Drying: 
                     In this technique, gelatin can be used as a supporting agent and as a matrix, 
mannitol as a bulking agent and sodium starch glycolate or croscarmellose or crospovidone are 
used as superdisintegrants. Tablets manufactured from the spray-dried powder have been 
reported to disintegrate in less than 20 seconds in aqueous medium. The formulation contained 
bulking agent like mannitol and lactose, a superdisintegrant like sodium starch glycolate & 
croscarmellose sodium and acidic ingredient (citric acid) and/or alkaline ingredients (e.g. sodium 
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bicarbonate). This spray-dried powder, which compressed into tablets showed rapid 
disintegration and enhanced dissolution. 
4. Sublimation: 
                      To generate a porous matrix, volatile ingredients are incorporated in the 
formulation that is later subjected to a process of sublimation. Highly volatile ingredients like 
ammonium bicarbonate, ammonium carbonate, benzoic acid, camphor, naphthalene, urea, 
urethane and phthalicanhydride may be compressed along with other excipients into a tablet. 
This volatile material is then removed by sublimation leaving behind a highly porous matrix. 
Tablets manufactured by this technique have reported to usually disintegrate in 10-20 sec. Even 
solvents like cyclohexane;benzene can be used as pore forming agents. 
 The basis of this technique is to add inert solid ingredients that volatilize readily, (e.g. camphor, 
ammonium bicarbonate, naphthalene, urea, urethane etc) to other tablet excipients and the 
mixture is then compressed into tablets. Volatile material is then removed via sublimation, which 
generate a porous structure. 
Koizumi et al applied the sublimation technique to prepare highly porous compressed tablets that 
were rapidly soluble in saliva. Mannitol and camphor were used as a tablet matrix material and 
subliming the material respectively.  Camphor was iminated by subliming in vacuum at 80 
0
C for 
30 minutes to develop pores in the tablets. 
Makino et al described a method of producing a fast dissolving tablet using water as a pore 
forming material. A mixture containing active ingredient and carbohydrates (glucose, mannitol, 
xylitol etc) were moistened with water (1- 3 %w/w) and compressed into tablets. The water was 
then removed yielding highly porous tablet that exhibited excellent ; 
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                        Fig No 1. 4 Steps involved in Sublimation Technology 
 
5. Direct Compression: 
                              Direct compression represents the simplest and most cost effective tablet 
manufacturing technique. This technique can now be applied to preparation of ODT because of 
the availability of improved excipients especially superdisintegrants and sugar based excipients. 
(a) Superdisintegrants: 
                                In many orally disintegrating tablet technologies based on direct 
compression, the addition of superdisintegrants principally affects the rate of disintegration and 
hence the dissolution. The presence of other formulation ingredients such as water-soluble 
excipients and effervescent agents further hastens the process of disintegration. 
 
(b) Sugar Based Excipients: 
                           This is another approach to manufacture ODT by direct compression. The use of 
sugar based excipients especially bulking agents like dextrose, fructose, isomalt, lactilol, 
maltilol, maltose, mannitol, sorbitol, starch hydrolysate, polydextrose and xylitol, which display 
high aqueous solubility and sweetness, and hence impart taste masking property and a pleasing 
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mouthfeel. Mizumito et al have classified sugar-based excipients into two types on the basis of 
molding and dissolution rate. 
Type 1 saccharides (lactose and mannitol) exhibit low mouldability but high dissolution rate. 
Type 2 saccharides (maltose and maltilol) exhibit high mouldability and low dissolution rate. 
 
 
 
 
 
 
 
 
 
 
 
 
               
 
         
                              Fig. No1.5 Compression of Sugar Based Excipients 
 
 
6. Mass-Extrusion: 
                        This technology involves softening the active blend using the solvent mixture of 
water-soluble polyethylene glycol and methanol and subsequent expulsion of softened mass 
through the extruder or syringe to get a cylinder of the product into even segments using heated 
blade to form tablet. The dried cylinder can also be used to coat granules for bitter drugs and 
there by achieve taste masking. 
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                                              2. REVIEW OF LITERATURE 
Adimoolan Senthil et al 2010
10
 Flunarizine HCL mouth dissolving tablets have been developed 
at 40-mg dose, with the intention off facilitating administration to patients experiencing 
problems with swallowing and hopefully, improving its poor oral bioavailability. 
 
Avani R Gosai et al
53
 Preparation, physicochemical characterization, dissolution and 
formulation studies of ondacetron cyclodextrin inclusion complexes The objective of this 
research was to prepare, characterize, and to study dissolution properties of inclusion complexes 
of ondacetron, with β-cyclodextrin and hydroxypropyl-β-cyclodextrin and to study effect of 
complexation on aqueous solubility and rate of dissolution in dissolution media. The highest 
improvement in solubility and in-vitro drug release were observed in inclusion complex prepared 
with HP-β-CD by kneading method. Improvement in solubility and in-vitro drug release of 
ondacetron was more with HP-β-CD as compared to β-CD 
 
Sudhir Bhardwaj et al (2010)
15
 Formulation and evaluation of fast dissolving tablet of 
aceclofenac.  Aceclofenac (anti-inflammatory and analgesic) was selected as the model drug. 
The poor aqueous solubility of the drug results in variable dissolution rate and hence poor 
bioavailability.  It was concluded that the fast dissolving tablets of poor soluble drug can be 
made by direct compression technique using selective super disintegrates showing enhanced 
dissolution, taste masking and hence better patient compliance and effective therapy.  
 
R Margret chandira et al 2010
8
  formulation and evaluation of mouth dissolving tablets of the 
etoricoxib. Etoricoxib is a new non-steroidal anti-inflammatory drug (NSAID) the main criteria 
for mouth dissolving tablets are to disintegrate or dissolve rapidly in oral cavity with saliva in 
15sec to 60sec with need of water. the disintegrants used should fulfill the criteria by the 
disintegrating the tablets in specified time limit in the present investigation variety of super 
disintegrants like primogel, kollidone, ac-di-sol, l-hpmc, l-hpc, were selected and tablets were 
prepared by direct compression method in different concentration like 4% and 8%. 
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Rakesh Pahwa et al 2010
1
 studies of Orally Disintegrating Tablets - Friendly to Pediatrics and 
Geriatrics to obviate the problem of dysphagia and to improve patient compliance, ODTs have 
gained considerable attention as preferred alternatives to conventional tablet and capsule 
formulations these the techniques render the disintegration of tablet rapidly and dissolve in 
mouth without chewing or additional water intake. 
 
Akbari B.V. et al (2010) 
6 
studies on formulation and in vitro evaluation of fast dissolving 
tablets of domperidone the formulations containing croscarmellose sodium, cross povidone, L-
HPC and cellactose80 as superdisintegrants, disintegrated faster compared to the formulation 
containing microcrystalline cellulose. in vitro drug release showed that almost drug was release 
in the range of 94-97% range in 10 minutes. Depending upon cumulative drug release, in vitro 
disintegration time, wetting time, there was found that direct compression method is better than 
wet granulation method. 
 
Indhumathi D et al (2010) 
11
study of design and optimization of orodissolving tablet of 
antidepressant drug by the superdisintegrants addition method mouth dissolving tablet offers a 
solution for pediatrics, geriatrics; psychiatric or mentally ill people and those have difficulty in 
swallowing tablets/capsules resulting in improved patient compliance in vitro dissolution studies 
show the release is in the following order of superdisintegrants: crospovidone > pregelatinized 
starch > croscarmellose > sodium starch glyacolate. Maximum in vitro dissolution was found to 
be with formulation f-7 and it clearly shows due to crospovidone (4%), this is also confirmed by 
in vivo pharmacokinetic studies. 
 
Debjit Bhowmik et al (2009)
2
 carried out the Fast Dissolving Tablet: An Overview Fast 
dissolving Tablets are disintegrating and/or dissolve rapidly in the saliva without the need for 
water. Some tablets are designed to dissolve in saliva remarkably fast, within a few seconds, and 
are true fast-dissolving tablets. Fast- or mouth dissolving tablets have been formulated for 
pediatric, geriatric, and bedridden patients and for active patients who are busy and traveling and 
may not have access to water. In some cases such as motion sickness, sudden episodes of allergic 
attack or coughing, and an unavailability of water, swallowing conventional tablets may be 
difficult. 
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Nitesh Patel et al (2011)
5
 performed Design and Characterization of Oral Dispersible Tablet of 
Ciinarizine. Cinnarizine is an Anti-histamine drug which is insoluble in water; hence the drug 
may be slowly or incompletely dissolves in the gastro-intestinal tract. So the rate of dissolution 
and therefore its bioavailability is less) In the present study an attempt has been made to prepare 
Oral Dispersible tablets of Cinnarizine by using Superdisintegrants–Crospovidone, Ac-de-sol, 
Sodium starch glycolate, level of addition to increase the rate of drug release from dosage form 
to increase the dissolution rate by adding surfactant SLS and hence its bioavailability. The 
Disintegration time of Fast Dissolving tablets were increased by the addition of concentration of 
Superdisintegrants. 
 
Raguia Ali Shoukri et al (2009)
12
 had study on vitro and in vivo evaluation of nimesulide 
lyophilized orally disintegrating tablets development of a lyophilized orally disintegrating tablet 
(ODT) that enhanced the in vitro dissolution and in vivo absorption of nimesulide, a drug with 
poor solubility and poor bioavailability is presented. 
 
C.P. JAIN et al 2009
13
 Carried out the formulation and evaluation of fast dissolving tablets of 
Valsartan. In this investigation the fast dissolving tablets of Valsartan were prepared using 
different Superdisintegrants by direct compression method. Wetting time of formulations 
containing Crospovidone was least and tablets showed fastest disintegration. The drug release 
from FDTs increased with increasing concentration of superdisintegrants and was found to be 
highest with formulations containing Crospovidone. The release of Valsartan from FDTs was 
found to follow non-Fickian diffusion kinetics. 
 
Bhupendra G Prajapati et al (2009)
 7
 A Review on Recent patents on Fast Dissolving Drug 
Delivery System. A allergic patient in the institutional setting can hide a conventional tablet 
under his or her tongue to avoid their daily dose of an atypical antihistamine. Fast-
dissolving/disintegrating tablets (FDDTs) are a perfect fit for all of these patients. FDDTs 
disintegrate and/or dissolve rapidly in the saliva without the need for water. Some tablets are 
designed to dissolve in saliva remarkably fast, within a few seconds, and are true fast-dissolving 
tablets. Others contain agents to enhance the rate of tablet disintegration in the oral cavity, and 
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are more appropriately termed fast disintegrating tablets, as they may take up to a minute to 
completely disintegrate 
 
D.Nagendrakumar et al (2010)
22
  have prepared Orodispersible tablets of ganisetron using 
various concentrations of the superdisintegrant agents like Ac-Di-Sol, crospovidone, sodium 
starch glycolate by direct compression method. 
 
Uddhav Bagul et al (2010)
45 
Reported formulation of Orodispersible capsules containing a 
soluble complex of the drug with beta-cyclodextrin. This work aimed to improve levocetrizine 
bioavailability by formulating it in Orodispersible capsules containing a soluble complex of the 
drug with beta-cyclodextrin. The Complexes were prepared by different methods and 
characterized by differential scanning calorimetry, X-ray diffraction, infrared spectroscopy and 
dissolution efficiency studies. Orodispersible capsule shells were prepared from conventional 
hard gelatin capsule shells by freeze-drying and evaluated by image analysis microscopy and 
moisture content estimation. Formulae containing the freeze-dried complex and different fillers 
were prepared and characterized for their flowability, moisture content and moisture absorption 
behavior. The Orodispersible capsules were evaluated in-vitro and in-vivo in comparison with 
levocetrizine commercial tablets (Levosiz). 
 
Vasanthakumar Sekar et al 2008
16
 In the present study an attempt has been made to prepare 
the immediate release tablets of telmisartan by using Polyplasdone XL-10 (Crospovidone) at 
intragranular, extragranular and partly intra and extragranular level of addition to increase the 
rate of drug release from dosage form to increase the dissolution rate and hence its 
bioavailability. The prepared granules and tablets were evaluated for their physiochemical 
properties and invitro dissolution study was conducted for the prepared tablets. It was concluded 
that the immediate release tablets with proper hardness, disintegration time and with increase rate 
of dissolution can be made using Polyplasdone XL-10 
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Avani F. Amin (2006)
18
 Emerging Trends In The Development Of Orally Disintegrating Tablet 
Technology new formulation trend is emerging and gaining popularity because it is 
easy administration and leads to better patient compliance. These dosage forms 
are placed in the mouth, allowed to disperse or dissolve in the saliva, and 
release the drug as soon as they come in contact with the saliva, thus obviating 
the need for water during administration. 
G. Abdelbar et al (2005)
19
 determination of the in vitro disintegration profile of rapidly 
disintegrating tablets and correlation with oral disintegration the assessment of the in vitro 
disintegration profile of rapidly disintegrating tablets (RDT) is very important in the evaluation 
and the development of new formulations of this type. so far neither the us pharmacopoeia nor 
the European pharmacopoeia has defined a specific disintegration test for rdt; currently, it is only 
possible to refer to the tests on dispersible or effervescent tablets for the evaluation of rdt’s 
disintegration capacity. The obtained time–distance profiles or disintegration profiles enabled the 
calculation of certain quantitative values as the disintegration onset (t1) and the total 
disintegration time (t2). These values were used in the characterization of the effect of test 
variables as the disintegration medium and temperature on the disintegration time of RDT. 
  
P. S. Zade et al (2009)
30
 have formulated fast dispersible tablets which disintegrated either 
rapidly in water to form a stabilized suspension or disperse instantaneously in the mouth to be 
swallowed without the aid of water. They employed a rotatable central composite design to 
predict the effects of the quantitative factors, mannitol and cross-povidone as well as 
compression force on the characteristics of tablet. 
 
Wolfgang Wienen et al 2000
21
 A Reviews on Telmisartan Novel, Long-Acting Angiotensin II-
Receptor Antagonist Telmisartan is a potent, long-lasting, nonpeptide antagonist of the 
Angiotensin II type-1 (AT1) receptor that is indicated for the treatment of essential hypertension. 
Telmisartan is not a prodrug and has a longer terminal elimination half-life than other 
commercially available sartans (24hrs), making it suitable for once-daily dosing. In animal 
models, telmisartan exhibits pronounced cardioand reno-protective effects in animals with 
severe, essential hypertension. In clinical studies, telmisartan shows comparable antihypertensive 
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activity to members of other major antihypertensive classes, such as ACE inhibitors, beta 
blockers and calcium antagonists. These trials have confirmed the placebo-like safety and 
tolerability of telmisartan in hypertensive patients. Based on these data, telmisartan offers 
advantages over other sartans and represents an important new treatment option for hypertension. 
 
UK Drug Information Pharmacists Group (2000)
22
 new medicines on the market of 
antihistaminic drugs. 
 
 DP Venkatesh et al
24
.the Formulation of taste masked oro-dispersible tablets of Ambroxol 
hydrochloride Ambroxol hydrochloride (HCL) is a potent mucolytic capable of inducing 
bronchial secretion Thus, in the work under taken, an attempt was made to mask the taste and to 
formulate into a oro-dispersible tablet by the complexation with ion exchange resins, which also 
acts as super disintegrating agents. Since, these tablets can be swallowed in the form of 
dispersion, it is suitable dosage form for pediatric and geriatric patients. Cation exchange resins 
like Indion-204 and Indion-234 were utilized for the sorption of drug. Drug-resinates was 
prepared in drug to resin ratio of 1:5 and 1:6. Also, the dispersion not showing any bitter taste, 
indicate the capability of ion exchange resins used, both as taste masking and super 
disintegrating agents 
 
Yourong Fu, et al
27
  Developments, Technologies, Taste-Masking and Clinical Studies Upon 
introduction into the mouth, these tablets were dissolve or disintegrate in the mouth in the 
absence of additional water for easy administration of active pharmaceutical ingredients. The 
popularity and usefulness of the formulation resulted in development of several FDT 
technologies. Th is review describes various formulations and tech nologies developed to 
achieve fast dissolution/dispersion of tablets in the oral cavity In particular; this review describes 
in detail FDT technologies based on lyophilization, molding, sublimation, and compaction, as 
well as approaches to enhancing the FDT properties, such as spraydrying, moisture treatment, 
sintering, and use of sugar-based disintegrants. 
 
 NG Raghavendra Rao et al 
23
 study on development of carbamazepine fast dissolving tablets: 
effect of functionality of hydrophillic carriers on solid dispersion technique An attempt has been 
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made for the development of fast dissolving tablets of the carbamazepine by solid dispersion 
methods, using different concentrations of croscarmellose sodium as super disintegrating agent 
and study the effect of various carriers on solid dispersion technique. The major problem of this 
drug is very low solubility in biological fluids and poor bioavailability after oral administration. 
The results concluded that fast dissolving tablets of poorly soluble drug, carbamazepine showing 
enhanced dissolution will lead to improved the bioavailability, improved the effectiveness and 
hence better patient compliance. 
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3. AIM AND SCOPE 
                       Before carrying out the study, its need should be clearly defined, such that the 
study present itself as a valuable contribution  to the field of study as well as a thoughtful 
investment of the researcher’s  time.   
The aim is to study is to develop and evaluate the oral dispersible tablet of Cinnarizine.  
 To enhanced the onset of action of Cinnarizine. 
 To enhance the solubility by using surfactant. 
 To prepared and cost effective direct compression methods. 
The main aim is to increase the disintegration time by using the different super-
disintegrants and to increase solubility of the cinnarizine drug by using surfactant. The present 
work is concerned with the formulation and characterization of cinnarizine orodispersable tablets 
for oral administration. Different drug compatible excipients were tried as filler and binder and 
the objective is to increase the release rate of dissolution by increase the release rate of drug from 
the solid oral dosage form by using different superdisintegrants. 
Cinnarizine bioavailability is near about 42% so it is benefit of once daily 
administration. The cinnarizine absorb from both i.e. oral cavity and gastro cavity. Half Life Bi-
exponential decay kinetics with a terminal elimination half-life of  approximately 3-4 hours The 
daily dose of cinnarizine for treatment of nausea and vomiting is minimum 25mg for adults for 
the management of histamine disorders, adult initially and for children dose greater than 12 years 
25 mg and for 6 to 12 years 25mg dose twise a daily.   
                          The objective of present work is to mask the taste of cinnarizine by using 
aspartame and menthol with physical mixture method and to develop the oral dispersible drug 
delivery system by simple and cost effective method. Scope of this dosage form is more 
comfortable for the patients who are suffering from dysphagia, the bedridden and the clinical 
condition where water intake is limited. 
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 The main objective is to develope oral dispersible tablets and provides the patients complains 
product.  
 To develop a physicochemical stable drug delivery system of cinnarizine.  
 To evaluate all the parameters of formulation in details including stability study. 
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4.  PLAN OF WORK 
1. Literature survey; 
2. Prefromulation studies; 
I) Identification and Characterization of Cinnarizine. 
 Melting point. 
 Infrared absorption spectrophotometer. 
.  
II) Development of standard calibration curve of Cinnarizine. 
3.      Formulation Design; 
 Development of oral dispersible tablet formulation using Three different super 
disintegrating agent. 
 Preparation of powder blend of drug and excipients 
 Preparation of oral dispersible tablet of cinnarizine by direct compression. 
4.     Assessment of powder blend; 
 Angle of repose 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner ratio 
5.  Compression of powder blend into tablet by direct compression method; 
6.  Post compression assessment of oro-dispersible tablets; 
 Weight variation  
 Hardness 
 Friability 
 Thickness  
 Wetting time 
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 Water absorption ratio 
       In-vitro disintegration  
      In-vitro dissolution 
         7. Stability studies; 
8.  Comparison of Best Formulation with all batches; 
        9.  Result and discussion; 
        10. Summary and conclusion; 
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5. DRUG PROFILE 
Cinnarizine
 (24) 
Chemical Formula:         C26H28N2 
Chemical Name:              1-trans-cinnamyl-4-diphenylmethyl-piperazine. 
IUPAC Name:                 1-(diphenylmethyl)-4-(3-phenylprop-2-en-1-yl)piperazine. 
Chemical Structure:         
 
 Drug Category:              Antihistamine (H1 – antagonist), calcium channel blocker. 
 Molecular Weight:        368.514 g/mol 
 State:                               Solid 
 Melting Point:                118-122
0
C
  
 Solubility:                       Soluble in ethanol or DMSO 
 Indication:                      For the treatment of motion sickness,vomiting and vertigo. 
 Dose:                               Minimum 25mg to Maximum 75mg 
 pKa:                                1.95,7.5  
 Mechanism of Action: 
                       Cinnarizine inhibits contraction of vascular smooth muscle cell by blocking L-
Type and T-Type voltage gated calcium channels. Cinnarizine has also been implicated in 
binding to dopamine D2 receptor, histamine H1 receptor, and muscarnic acetylcholin receptor. 
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Pharmacodynamics:  
                       Cinnarizine inhibits contractions of vascular smooth muscle cells by blocking 
calcium channels. Cinnarizine increases erythrocyte deformability and decreases blood viscosity 
in vitro. Cinnarizine inhibits stimulation of the vestibular system 
Absorption: 
                     Cinnarizine is well absorbed from the gastrointestinal tract. The pharmacokinetics 
of a single oral dose in healthy volunteers have been studied. Peak plasma concentrations in 
fasting subject are seen at 1- 3 h following administration of 75 mg cinnarizine, and are not 
significantly affected by the formulation of the drug. The plasma half-life is 3.040.83 h (mean  
SD).             
Disrtibution: 
                   Cinnarizine is widely and rapidly distributed throughout body tissues, as would be 
expected for a highly lipid soluble drug. There is rapid absorption of the administered compound 
from the GI tract and peak tissue levels occur within 1 hour, except in the gonads where the peak 
is reached only after 4-8h. For the liver, the peak level corresponded to 6% of the administered 
dose and for all other tissues (i.e., brain, heart, lung, spleen, kidneys) it was less than 0.5%. 
Plasma protein binding of cinnarizine is 91%. 
Metabolism and Excreation: 
                  Cinnarizine undergoes a number of biotransformations, which include N-oxidation, 
C-oxidation, and oxidative cleavage of the drug. It undergoes metabolism and has a half-life of 3 
to 4 hours after oral administration. Human data on the metabolism and excretion of cinnarizine 
are limited but suggest that cinnarizine undergoes extensive metabolism.  
.             Unchanged drug was found only in very small quantities in the urine, but more variable 
amounts were found in the feces. The major urinary metabolites are cinnarizine-n-oxide and 
benzhydrol and major fecal metabolites are benzhydrylpiperazine and p-hydroxybenzophenone. 
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Dosage and administration: 
                    The recommended dose for treatment of vestibular symptoms in adult and children 
over 12 years is 30mg three times daily. For children from 5-12 years half the dose is 
recommended i.e., 15 mg three times daily. 
                    For prophylaxis of motion sickness, 75 mg for adults and Children from 5-12 years 
should take half the adult dose. 
Drug Interactions: 
                    Cinnarizine may potentiate  the effect of antidepressant and alcohol. Antacid 
medicines and H2 blocker, accelerates resorption of preparation, reducing acidity of the stomach 
fluid. Nootrope agent and vasodilators increase cinnarizine effect.  
  Adverse reactions: 
                   Cinnarizine may potentiate the effect of antidepressant and alcohol. Antacid 
medicines and H2 blockers accelerates resorption of preparations, reducing acidity of stomach 
fluid.Nootrope agent and vasodilators increase cinnarizine effect. 
Contraindications: 
                    In patients with known hypersensitivity to cinnarizine. Patients with a diagnosis of 
parkinson’s disease should not be given cinnarizine. Cinnarizine should be used with caution in 
hypotensive patients. The safety of cinnarizine tablets in pregnant and lactating women has not 
been established. 
 
  Storage: 
                   Store in cool and dry place,  
                  Away from direct heat and light.   
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6. Superdisintegrant Profile 
A) Crosspovidone 
IUPAC name:               Polyvinylpyrollidone 
Synonym:                      PVP, Povidone, PolyvidonePoly [1-(2-oxo-1-pyrrolidinyl) ethylene] 1- 
                                       Ethenyl-2-pyrrolidon homopolymer 1-Vinyl-2-pyrrolidinon-Polymere 
                                       Copovidone PNVP. 
Molecular formula:     (C6H9NO) n 
Molar mass:                  2.500 - 2.5000.000 g·mol
−1 
Appearance:                 white to light yellow, hygroscopic, amorphous powder. 
Density:                         1.22 gm/cm³ 
Melting point:              110 - 180 °C (glass temperature), 
Solubility:                    Completely insoluble in water, acids, alkalis, and all organic solvents.  
                                      Hygroscopic. Swells rapidly in water. Rapidly disperses in water, but  
                                      Does not gel even after prolonged exposure. 
Physical Characteristics: pH (10% slurry): 5.0 – 8.0 Moisture (Karl-Fisher): £ 5.0%  
                                                              Table. No. 6.1  
Product 
Typical Average 
Particle size 
(microns) 
Tap 
Density 
(g/cc) 
Bulk Density 
(g/cc) 
Polyplasdone XL 100 0.3 0.2 
Polyplasdone XL-
10 
30 0.5 0.3 
Polyplasdone INF-
10 
11 0.5 0.4 
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     Properties PVP is soluble in water and other polar solvents. When dry it is a light flaky 
powder, which readily absorbs up to 40% of its weight in atmospheric water. In solution, it has 
excellent wetting properties and readily forms films. This makes it good as a coating or an 
additive to coatings. 
Uses                    
                    The monomer is extremely toxic to aquatic life. 
1. Medical 
                           The polymer PVP was used as a blood plasma expander for trauma victims after 
the first half of the 20th century. It is used as a binder in many pharmaceutical tablets; it simply 
passes through the body when taken orally. However, autopsies have found that crospovidone 
does contribute to pulmonary vascular injury in substance abusers who have injected 
pharmaceutical tablets intended for oral consumption. The long-term effects of crospovidone 
within the lung are unknown. PVP added to iodine forms a complex called povidone-iodine that 
possesses disinfectant properties. This complex is used in various products like solutions, 
ointment, pessaries, liquid soaps and surgical scrubs. It is known for instance under the trade 
name Betadine. 
2. Technical 
          PVP is also used in many technical applications: 
 As adhesive in glue stick and hot melts 
 As special additive for batteries, ceramics, fibreglass, inks, inkjet paper and in the 
chemical-mechanical planarization process 
 As emulsifier and disintegrant for solution polymerization 
 As photoresist for cathode ray tubes (CRT) 
 use in aqueous metal quenching 
 for production of membranes, such as dialysis and water purification filters 
 As a binder and complexation agent in agro applications such as crop protection, seed 
treatment and coating 
 As a thickening agent in tooth whitening gels 
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 As an aid for increasing the solubility of drugs in liquid and semi-liquid dosage forms 
(syrups, soft gelatine capsules) and as an inhibitor of recrystallisation 
 As an additive to Doro's RNA extraction buffer 
3.  Other uses 
                     PVP is also used in personal care products, such as shampoos and toothpastes, in 
paints, and adhesives that must be moistened, such as old-style postage stamps and envelopes. It 
has also been used in contact lens solutions and in steel-quenching solutions. PVP is the basis of 
the early formulas for hair sprays and hair gels, and still continues to be a component of some. 
As a food additive, PVP is a stabilizer and has E numberE1201. PVPP is E1202. It is also used 
in the wine industry as a fining agent for white wine. Other references state that polyvinyl 
pyrrolidone and its derivatives are fully from mineral synthetic origin. Therefore, its use in the 
production should not be a problem for vegans. 
                   In molecular biology, PVP can be used as a blocking agent during Southern blot 
analysis as a component of Denhardt's buffer. It is also exceptionally good at absorbing 
polyphenols during DNA purification. Polyphenols are common in many plant tissues and can 
deactivate proteins if not removed and therefore inhibit many downstream reactions like PCR. 
Safety 
                The USFDA has approved this chemical for many uses and it is generally considered 
safe. However, there have been documented cases of allergic reactions to PVP/povidone, 
particularly regarding subcutaneous (applied under the skin) use and situations where the PVP 
has come in contact with autologous serum (internal blood fluids) and mucous membranes. For 
example, a boy having an anaphylactic response after application of PVP-I (PVP-Iodine) for 
treatment of impetigo was found to be allergic to the PVP component of the solution. A woman, 
who had previously experienced urticaria (hives) from various hair products, later found to 
contain PVP, had an anaphylactic response after povidone-iodine solution was applied internally. 
She was found to be allergic to PVP. In another case, a man experiencing anaphylaxis after 
taking acetaminophen tablets orally was found to be allergic to PVP.  
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                     Povidone is commonly used in conjunction with other chemicals. Some of these, 
such as iodine, are blamed for allergic responses, although testing results in some patients show 
no signs of allergy to the suspect chemical. Allergies attributed to these other chemicals may 
possibly be caused by the PVP instead. 
B) Croscarmellose sodium   
Synonyms                        :     Ac-Di-Sol; Cross linked carboxymethylcellulose sodium;  
                                             explocel; modified cellulose gum; primellose; solutab.  
Chemical name                :    Cellulose, carboxymethyl ether, sodium salt, cross linked.   
Nonproprietary name      :    BP: Croscarmellose sodium. 
                                                PhEur: Carmellosumnatricumconexum. 
                                                USPNF: Croscarmellose sodium.  
Functional category         :    Tablet and capsule disintegrant. 
Molecular weight             :    90000 - 700000 
Melting point                   :    It brown at approximately 227
0
C chars at approximatrly252
o
C 
Description                       :   Croscarmellose sodium occurs as an odorless, white or grayish  
 
                                               White Powder. 
 
Solubility                        :   Insoluble in water, but rapidly swells 4 to 8 times it’s original  
 
                                            Volume on contact with water.  
Application                    :   Croscarmellose sodium is used in oral pharmaceutical formulation as 
                                            a disintegrant for capsules, tablets, and granules.  
           In tablet formulations, Croscarmellose sodium may be used in both direct 
compression and wet granulation processes. When used in wet granulations, the Croscarmellose 
sodium should be added in both the wet and dry stages of the process (intra and extra 
granularly) so that the wicking and swelling ability of the disintegrant is best utilized. 
Croscarmellose sodium at concentrations up to 5% w/w may be used as a tablet disintegrant, 
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although normally 2% w/w is used in tablets prepared by direct compression and 3% w/w in 
tablets prepared by a wet granulation process.     
Stability and storage conditions: 
                                  Croscarmellose sodium is a stable though hygroscopic material. A modal 
tablet formulation prepared by direct compression, with Croscarmellose sodium as a disintegrant, 
showed no significant difference in drug dissolution after storage at 30 
0
C for 14 months. 
Croscarmellose sodium should be stored in a well-closed container in a cool, dry place. 
C) Cellactose 80  :  
Synonyms:                    Elcema P-100, Ludipress. 
Nonproprietary names:  BP: Cellactose 80. 
                             PhEur:  Alfa-lactose monohydrate 
                             USPNF: Cellactose 80. 
Functional category:  Tablet and capsule disintegrant.  
 Description: 
                          Cellactose 80 is a spray dried mixture of 75 parts lactose monohydrate and 25 parts 
cellulose powder.Cellactose 80 is a white or almost white, odourless and tasteless powder, partly soluble 
in water. Apart from good flowability, it has good compactibility. The compactibility is attributed to a 
synergistic effet of consolidation by fragmentation of lactose and plastic deformation of cellulose. 
Because the lactose covers the cellulose fibers, moisture sorption is much lower than that of 
microcrystalline cellulose alone. 
Angle of repose: 32 – 350 
Density poured: 380 (g/l) 
Density tapped: 500 (g/l) 
Hauser ratio:1.24 
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                                             Certificate of Analysis  
                                  (Molkerei MEGGLE Wasserburg Gmbh & Co. KG) 
                                                       Table no.6.2 
 
Method/Specification Result 
Identification 
A.Cellactose 80 
 
B. Lactose 
 
C. Cellulose powdered 
 
 
 
Tests 
pH 
Loss on drying 
Water 
Sulphated ash 
Heavy metals 
 
 
Partical size distribution 
 
 
IR-absorption 
Ph.Eur./Monogr. Cellactose 80 
Thin layer chromatography 
Ph.Eur./Monogr. Cellactose 80 
1.Method A 
Ph.Eur./Monogr. Cellactose 80 
2.Method B 
USP/NF/Monogr. Cellactose 80 
 
Ph.Eur./Monogr./4.0-7.0  
Ph.Eur./Monogr./NMT 3.5 % 
Ph.Eur./Monogr./4.0-7.0 % 
Ph.Eur./Monogr./NMT 0.2 % 
Ph.Eur./Monogr./NMT 5 ppm 
 
 
 
Conforms 
 
 
Conforms 
 
 
Conforms 
 
 
Conforms 
 
 
 
5.4 
 
1.1 
 
4.41 
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Microbial contamination 
Total viable aerobic count 
Mould 
Yeasts 
Escherichia coli 
Salmonella spp. 
Assay 
Lactose as  monohydrate 
calculated on dried basis 
Cellulose powdered  
calculated on dried basis 
 
 
 
<32 µm NMT 20 % 
<160 µm 35 – 65 % 
<250 µm NLT 80 % 
 
 
 
Ph. Eur./NMT 10
2
/g 
Ph. Eur./NMT 10/g 
Ph. Eur./NMT 10/g 
Ph. Eur./negative  /10g 
Ph. Eur./negative  /10g 
 
Monogr./ 73,0-77,0 % 
 
 
Monogr./ 23,0-27,0 % 
0.21 
 
conforms 
 
 
 
 
conforms 
 
conforms 
 
conforms 
 
 
 
 
3 
 
 
 
Feature: 
 Good content uniformity through low segregation tendency of the active ingredient 
 Ideal surface structure of the cores for easy and economical coating 
 Compaction of delicate active ingredients through excellent compressibility 
 Consistent tablet hardness through constant lactose / cellulose ration 
 High weight consistency at all compaction speeds through good flowability 
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 High degree of whiteness of tablets 
 
Organic volatile impurities: 
                     It is stated that no organic solvents are used in the manufacturing process of Cellactose  80. 
Storage: 
                At room temperature, in tightly closed containers, under dry and odour free conditions. 
 
Pharmaceutical Applications: 
o Herbal extract tablets 
o Chewable tablets 
o Mineral salt tablets 
o Cores for coating 
o Oblong tablets 
Regulatory status:  
                               Included in the FDA inactive ingredients guide (oral capsule and tablets) 
included in nonparental medication licensed in the UK 
D) Microcrystalline cellulose (MCC)    : 
 Synonyms                      :          Avicel, cellulose gel, emocel, fibrocel, tabulose, vivacel 
.Chemical name            :          Cellulose 
Chemical formula        :          (C6H10O5) 
Molecular weight          :         36,000 
Non proprietary name   :       BP Microcrystalline cellulose 
                                                 PhEur: Cellulosum microcrystalline cellulose 
                                                 USPNF: microcrystalline cellulose 
Melting point               :          Chars at 260-270
O
C 
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Nominal mean partical size:   100µm 
Specific surface area   :          1.21-1.30m
2
/g 
Description                   : 
                                   Microcrystalline cellulose is purified partially depolymerized cellulose that 
occurs as a white colored, odourless crystalline powder composed of porous particles. It is 
commercially available at different size grades, which have different properties and applications. 
Property of some commercially available grade of microcrystalline cellulose: 
                                                Table. No. 6.3 
Grade  Nominal mean partical size 
(µm) 
Moisture content (%) 
Avicel PH 101                   50                  ≤ 5.0 
Avicel PH 102                  100                  ≤ 5.0 
Avicel PH 103                   50                  ≤ 3.0 
Avicel PH 105                   20                  ≤ 5.0 
Avicel PH 112                  100                  ≤ 1.5 
Avicel PH 113                   50                  ≤ 1.5 
Avicel PH 200                  180                  ≤ 5.0 
Avicel PH 301                   50                  ≤ 5.0 
Avicel PH 302                  100                  ≤ 5.0 
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Pharmaceutical application of Avicel: 
                                                Table. No. 6.4 
USE  Concentration (%) 
Adsorbent  20-90 
Anti-adherent 5-20 
Capsule diluents 20-90 
Tablets disintegrant 5-15 
Tablet binder/ Diluents 20-90 
 
Application:   
                          Microcrystalline cellulose is widely used in pharmaceuticals primarily as 
diluents in oral tablet and capsule formulations, where it is used in both wet granulation and 
direct compression processes..in addition to use as diluents, MCC also has some lubricant and 
disintegrant properties that make it useful in tableting. It is used as tablet disintegrant in 5-20% 
concentration, while as diluents 20-29% concentration is employed. 
E) Aspartame : 
Non-proprietary Name:    USPNF 
Synonyms:                  3-Amino-N- (α-carboxyphenethly) succinamic acid N-methyl ester: 3 
                                    -Amino-N-(α-methoxycarbonylphenethyl) succinamic acid; APM aspartyl 
                                   -L-phenylamine methyl ester: canderel: E951: Equal; methyl N -α- L 
                                   -aspartyl-L-phenylalaninate; NutraSweet; Sanecta; SC -18862; Tri-Sweet. 
Chemical Name:      N-α-L-aspartyl-L-phenylalanine 1-methyl ester. 
Empirical Formula: C14H18N2O5 
Molecular Formula : 294.31 
Melting Point:           246-247
O
C 
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Density (bulk):            0.4-0.5 g/cm
3
 for granular grade. 
                                     0.3-0.4 g/cm
3
 for powder grade. 
pH:                              ≤4.0-6.5 (0.8%w/v aqueous solution). 
Functional Category:   sweetening Agent. 
Description:                  Aspartame occurs as an off-white almost odourless, crystalline powder 
                                       with an intensely sweet taste.  
Application in Pharmaceutical Formulation or Technology: 
                         Aspartame is used as an intense sweetening agent in beverage product, food 
product, and table-top sweetener and in pharmaceutical preparations including tablets powder 
mixture and vitamin preparation. It enhances flavour system and can be used to mask some 
unpleasant taste characteristics the approximate sweetening power is 180-200 times of sucrose. 
                           Unlike some other intense sweetener, aspartame is metabolized in the body and 
consequently has some nutritive value 1g provide approximate 17 kJ (4 kcal). However in 
practice, the small quantity of aspartame consumed provides a minimal nutritive effect. 
Stability and Storage condition:  
                            Aspartame is stable in condition. In the presence of moisture, hydrolysis occur 
to form the degradation product L-aspartyl-L-phenylalanine and 3-benzyl-6-carboxymethyl-2, 5-
diketonepiperazine. A third degradation product is also know, β-L-aspartyl-L-phenylalanine 
methyl ester. For stability profile at 25
o
C in aqueous buffers. 
                           Stability in aqueous solution has been enhanced by the addition of cyclodextrins 
and by the addition of polyethylene glycol 400 at pH 2. However at pH 3.5-4.5 stability is not 
enhanced by the replacement of with water solvent.  
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F)  Magnesium stearate: 
Non-proprietary name: BP: Magnesium stearate 
                                        PhEur: Magnesiistearas 
                                        USPNF: Magnesium stearate 
Synonyms:                     E 572, Hyqual, Magnesium salt. 
Chemical name:            Octadecanoic acid Magnesium Salt. 
Empirical Formula:      C36H70MgO4 
Molecular Formula:      591.27 
Functional category:     Tablet and capsule lubricant 
Flowability:                    Poorly flowing, cohesive powder 
Melting point:                88.5
o
C 
Moisture content:          3.85% 
Solubility:                       Practically insoluble in ethanol, ethanol 95%, ether and water ; slightly  
                                         soluble in warm benzene and warm ethanol 95%. 
Description:  Magnesium stearate is a fine, white, precipitated or milled, implantable powder of 
low bulk density having a faint, characteristic odour and taste, the powder is greasy to touch and 
readily adheres to the skin. 
Polymerisation: 
                       A trihydrate, acicular from and a dehydrate lamellar form have been isolated with 
the latter processing the better lubricating properties. 
Stability and storage condition: 
                     Magnesium stearate is stable and should be stored in a well-closed container in a 
cool and dry place. 
Incompatibilities: 
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                       Incompatible with strong acid, alkalis and iron salts. Avoid mixing with strong 
oxidizing material. 
Safety:  
                Magnesium stearate is used as a pharmaceutical excipients and is generally regarded as 
being nontoxic following oral administration. However oral consumption of large quantities may 
result in some laxative effect or mucosal irritation. Inhalation of magnesium stearate powder is 
harmful and has resulted in fatalities. 
Handling precaution:  
                     Observe normal precaution appropriate to the circumstances and quantity of 
material handled. Eye protection and glove are recommended 
G) Mannitol 
Chemical name:          hexanitro mannitol 
Synonym:                     mannitol hexanitrate, nitromannite, nitromannitol, nitranitol, mannitrin 
IUPAC:                        (2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol-1,2,3,4,5,6-hexanitrate 
Molecular formula:      C6H8N6O18 
Molar mass:                      452.15712 
Density:                               1.604 g/cc 
Melting point:               112 °C = 234 °F 
Formula:                       C6H14O6 
Mol. mass:                     182.172 
Bioavailability: 
                       In pharmacology, bioavailability is used to describe the fraction of an 
administered dose of unchanged drug that reaches the systemic circulation, one of the principal 
pharmacokinetic properties of drugs. By definition, when a medication is administered 
                                                                      SUPERDISINTEGRANT PROFILE 
 
DEPARTMENT OF PHARMACEUTICS, NCP, ERODE Page 48 
 
intravenously, its bioavailability is 100%. However, when a medication is administered via other 
routes (such as orally), its bioavailability decreases (due to incomplete absorption and first-pass 
metabolism) or may vary from patient to patient (due to inter-individual variation).             
Bioavailability is one of the essential tools in Pharmacokinetics, as bioavailability must be 
considered when calculating dosages for non-intravenous routes of administration. 
                           For dietary supplements, herbs and other nutrients in which the route of 
administration is nearly always oral, bioavailability generally designates simply the quantity or 
fraction of the ingested dose that is absorbed. Bioavailability is defined slightly differently for 
drugs as opposed to dietary supplements primarily due to the method of administration and Food 
and Drug Administration regulations. 
Use: This polyol is used as an osmotic diuretic agent and a weak renal vasodilator Mannitol is 
also the first drug of choice for the treatment of acute glaucoma in veterinary medicine. It is 
administered as a 20% solution IV. It dehydrates the vitreous humor and, thus, lowers the 
intraocular pressure. However, it requires an intact blood-ocular barrier to work. Mannitol can 
also be used to temporarily encapsulate a sharp object (such as a helix on a lead for an artificial 
pacemaker) while it is passed through the venous system. Because the mannitol dissolves readily 
in blood, the sharp point will become exposed at its destination. 
Mannitol may be administered in cases of severe Ciguatera poisoning. Severe ciguatoxin, or 
"tropical fish poisoning" can produce stroke-like symptoms. Mannitol is the primary ingredient 
of Mannitol Salt Agar, a bacterial growth medium, and is used in others. In oral doses larger than 
20 g, mannitol acts as an osmotic laxative, and is sometimes sold as a laxative for children 
Toxicology: Mannitol is contraindicated in patients with anuria and Congestive Heart Failure 
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H)  Menthol  
IUPAC name:                 (1R,2S,5R)-2-isopropyl-5-methylcyclohexanol 
Synonym:                    3-p-Menthanol, Hexahydrothymol, Menthomenthol, peppermint camphor 
Molecular formula:      C10H20O 
Molar mass:                    156.27 g mol−1 
Appearance:                White or colourless crystalline solid 
Density:                             0.890gcm
−3, solid (racemic or (−)-isomer) 
Melting point:             36–38 °C (311 K), racemic 42–45 °C (318 K), (−)-form (α) 35-33-31 °C,  
                                      (−)-isomer 
Boiling point:              212 °C (485 K) 
Solubility in water:     Slightly soluble, (−)-isomer 
Thermodynamic data:  Phase behaviour Solid, liquid, gas 
Applications 
 In non-prescription products for short-term relief of minor sore throat and minor mouth 
or throat irritation  
Examples: lip balms and cough medicines 
 As an antipruritic to reduce itching 
 As a topical analgesic to relieve minor aches and pains such as muscle cramps, sprains, 
headaches and similar conditions, alone or combined with chemicals like camphor, 
eucalyptus oil or capsaicin. In Europe it tends to appear as a gel or a cream, while in the 
US patches and body sleeves are very frequently used  
Examples: Balm, or Icy Hot patches or knee/elbow sleeves 
 In decongestants for chest and sinuses (cream, patch or nose inhaler)  
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Examples: Vicks Vaporub, Mentholatum, vapoRem 
 In certain medications used to treat sunburns, as it provides a cooling sensation (then 
often associated with aloe) 
 As an additive in certain cigarette brands, for flavour, to reduce the throat and sinus 
irritation caused by smoking. 
 Commonly used in oral hygiene products and bad-breath remedies like mouthwash, 
toothpaste, mouth and tongue-spray, and more generally as a food flavour agent; e.g. in 
chewing gum, candy 
 In a soda to be mixed with water to obtain a very low alcohol drink or pure (brand 
Ricqlès which contains 80% alcohol in France). The alcohol is also used to alleviate 
nausea, in particular motion sickness, by pouring a few drops on a lump of sugar. 
 As a pesticide against tracheal mites of honey bees 
 In perfumery, menthol is used to prepare methyl esters to emphasize floral notes 
(especially rose) 
 In first aid products such as "mineral ice" to produce a cooling effect as a substitute for 
real ice in the absence of water or electricity (Pouch, Body patch/sleeve or cream) 
 In various patches ranging from fever-reducing patches applied to children's foreheads to 
"foot patches" to relieve numerous ailments (the latter being much more frequent and 
elaborate in Asia, especially Japan: some varieties use "functional protrusions", or small 
bumps to massage ones feet as well as soothing them and cooling them down) 
 In some beauty products such as hair-conditioners, based on natural ingredients (e.g. St. 
Ives). 
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7. EXPERIMENTAL 
7.1 MATERIALS USED 
             Table No. 7.1: List of materials used and their suppliers 
 
  
SR. 
NO. 
MATERIALS SUPPLIERS 
1 
               
               Cinnarizine 
 
 
Glenmark API Private LTD 
 
2 Cellactose 80  
 Molkerei MEGGLE Wasserburg 
GmbH & Co.KG. 
 
3 Crosspovidone  
BOAI NKY Pharmaceuticals.LTD, 
CHINA 
4 Croscarmellose sodium 
MAXWELL Life science 
PVT.LTD,Mumbai 
5 Aspartame  
Changmao Biochemical 
Engineering co.LTD, China  
      6 
 
Microcrystalline cellulose 
(Avicel PH-102) 
Vijlak Phrma Jinnaram, Mandal 
7 Lactose  
SCHREIBER Dynamix 
Dairies.LTD Baramati 
8 Mannitol  
Shandong Tianli 
Pharmaceutical.co.LTD,China 
9 Menthol  Bright Aromatics 
10 Magnesium Stearate 
Nitika Chemicals Ltd. Nagpur 
 
11 Hydrochloric acid 
Thermo Fisher Scientific India 
PVT.LTD. Mumbai  
12 Sodium hydroxide pellets 
Thermo Fisher Scientific India 
PVT.LTD. Mumbai 
13 
Potassium dihydrogen 
Orthophosphate 
      Qualjgens Fine Chemicals, 
              Navi Mumbai 
14 Potassium chloride 
Ranbaxy Fine Chemicals Ltd., 
New Delhi 
15 Potassium bromide (IR) 
Qualigence Laboratories,  
Navi Mumbai. 
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7.2 INSTRUMENTS USED 
           Table No. 7.2: List of instruments used and their manufacturer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SR. 
NO. 
INSTRUMENTS MANUFACTURER 
1 
Rotary Press Tablet 
Compression Machine 
RIMEK Minipress-I, 
Karnavati Engineering Ltd., 
Mehsana, Gujarat. 
2 Dhona Balance 
Dhona Instruments Pvt. Ltd., 
Kolkata. 
3 Digital pH meter 
Model No. NIG 333, 
Naina Solaris Ltd. India. 
4 Monsanto Hardness tester 
Cadmach Machinery Pvt. Ltd., 
Ahmedabad. 
5 Roche Friabilator USP XVIII 
Model No. EF-1W, 
Electrolab Pvt. Ltd., Goregaon (E), 
Mumbai. 
6 Sieves Sethi Standard Test Sieves 
7 
Double Beam  
UV-Spectrophotometer 
Techcomp UV 2300 
8 Dissolution Apparatus USP XVIII 
Model No. TDT – 06P, 
Electrolab Pvt. Ltd., Goregaon (E), 
Mumbai. 
9 FTIR Spectrophotometer 
Model No. 8400 S, 
Shimadzu Asia Pacific Pvt. Ltd., 
Singapore. 
10 Digital Vernier Caliper ASAHI, India. 
11 Ultrasonicator PCI, Mumbai. 
12 Magnetic stirrer 
Model No. 1MLH,  
Remi, Mumbai 
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7.3 PREFORMULATION STUDIES 
Identification test for Cinnarizine;
 
 
Melting point: The melting point of Cinnarizine was determined by capillary method and 
checked, whether it complies with the reported ones or not. 
Infrared absorption Spectrophotometry: 
                    Cinnarizine was dried in hot air oven at 50
0
C for 2 hours. The samples were 
prepared by mixed it thoroughly in mortar and pestle. This physical mixture was compressed 
under pressure of 10 Ton/nm
2
 and converted in a circular disc. This disc was then placed in the 
scanning slot of Fourier Transform Infra-red (FT-IR) Spectrophotometer and scanned at range 
from 400 to 4000 cm
-1 
to obtain the FTIR of cinnarizine. Compared the spectrum with reference 
spectrum given in BP 2007. 
 
Preparation of stock solution of Cinnarizine:
 
 
                 Weigh accurately 100.0 mg of Cinnarizine and dissolve it in 100.0ml of dilution 
media (respective 1M NAOH). The strength of solution was found to be 1 mg/ml. Respective 
dilutions were prepared using stock solution (A). 
                 After then about 10.0 ml of stock solution was accurately pipette into a 100.0 ml of 
volumetric flask and make up the volume with the dilution media to get stock solution of 
strength 100 μg/ml. The respective dilutions were prepared using stock solution (B). 
 Preparation of standard calibration curve: 
           To make the dilutions of Cinnarizine ranging from 5 μg/ml to 25 μg/ml appropriate 
volumes of  stock solution i.e. 5, 10, 15, 20 and 25 ml was pipetted and volume was made up to 
100.0 ml with the dilution  media (1M NAOH). The absorbance was measured of the prepared 
dilution in UV-Visible spectrophotometer at 254 nm (IP) wavelength and calibration curve 
between absorbance and concentration was plotted. 
                        To obtain 5,10,15,20,25,30 µg/ml of the sample and the absorbance was measured 
at 254 nm by UV visible spectrophotometer.   Same procedure was repeated for Acidic buffer P
H
 
1.2 and basic medium (1M NAOH) to prepare standard curve. Reagents required for preparation 
of pH 1.2 hydrochloric acid buffer and basic medium are given as follows: 
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Preparation of Reagents: 
The reagents were prepared as per IP. 
a) Preparation of 1M Sodium hydroxide (NAOH) solution: NAOH pallets dissolve with 
distilled water so that final solution contains 42 g of sodium hydroxide in 1000.0 ml to obtain 
1M sodium hydroxide solution. 
b) Preparation of 0.2M hydrochloric acid (HCl) solution: Conc. HCl diluted with distilled 
water so that final solution contains 7.292 g of hydrochloric acid in 1000.0 ml to obtain 0.2M 
hydrochloric acid solution. 
a) Preparation of 0.2M potassium chloride (KCl) solution: Dissolve approx. 14.911 g of 
potassium chloride in distilled water and diluted to 1000.0 ml with distilled water to obtain 
0.2M potassium chloride solution. 
b) Preparation of dilution media (pH 1.2 hydrochloric acid buffer): About 250.0 ml of 0.2M 
potassium chloride solution was placed in a 1000.0 ml volumetric flask. To this, about 425.0 
ml of 0.2M hydrochloric acid was added and then volume was adjusted to 1000 ml with 
distilled water. Then prepared solution was tested using pH meter. The pH of solution was 
adjusted to pH 1.2 with the help of 0.2M hydrochloric acid. 
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8. ASSESSMENT OF PREPARED FORMULATION
 (7) 
 
8.1)  Pre-compression assessment of physical parameters of mixture blend 
Different physical properties of mixture blend were evaluated using following methods. 
Angle of Repose: 
               It is the maximum angle that can be obtained between the freestanding surface of a 
powder heap and horizontal plane. Such the measurement gives at least a qualitative assessment 
of internal cohesive and frictional effects under low level of external loading, as might apply in 
powder mixing or in tablet die or capsule shell filling operation.    
             Angle of repose method, which results in so-called dynamic angle, is preferred, since 
they most closely mimic the manufacturing situation, in which powder is in motion, with care, 
dynamic angle of repose measurement can be replicated with the relative standard deviations of 
approximately 2% they are particularly sensitive to changes in particle size distribution and to 
moisture content and they provide rapid means of monitoring significant batch difference in 
these respects. 
                 Angle of repose is calculated by fixed funnel method. In this method funnel was fixed 
to a stand in such a way that the lower tip of funnel was 2 cm above the surface. A  paper was 
placed on flat surface. The blend was allowed to fall freely on the paper through the funnel, till 
the tip of heap formed just touches the funnel. The height and radius of heap was noted and from 
this angle of repose was determined with the help of given formula. 
The formula for calculating angle of repose is: 
                                        tan θ = h/r                         θ = tan-1(h/r) 
                        Where, 
                                    θ = angle of repose 
                                    h = height of the powder cone  
                                    r = radius of the circumference 
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                Table No: 8.1 Angle of repose as an indication of powder flow properties: 
Sr. no. 
Angle of repose 
( Degrees) 
Type of flow 
1 < 20 Excellent 
2 20-30 Good 
3 30-34 Passable 
4 > 40 Very poor 
 
Bulk Density:  
          Bulk density is indicative of the packing of the particles and as such is greatly 
influenced by the size of blend. Both loose bulk density (LBD) and tapped bulk density (TBD) 
were determined. A quantity of 2 g of powder from each formula, previously lightly shaken to 
break any agglomerates formed, was introduced into a 10 ml measuring cylinder. After the initial 
volume was observed, the cylinder was allowed to fall under its own weight onto a hard surface 
from the height of 2.5 cm at 2 second intervals. The tapping was continued until no further 
change in volume was noted. LBD and TBD were calculated using the following formulas, 
LBD = W/V0 
TBD = W/Vt 
                                                     Where, W = weight of the powder 
                                                      V0 = volume of packing 
                                                       Vt = tapped volume of the packing 
Tapped Density: 
            It is the ratio of total mass of the powder to the tapped volume of powder. The volume 
was measured by tapping the powder for 500 times. Then the tapping was done for 750 times and 
the tapped volume was noted. The tapped density was calculated by using the following formula, 
                                                Pt = M/Vt 
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      Where, Pt = Tapped Density 
                    M = Weight of the sample in gm 
                   Vt = tapped volume of blend in cm
3
 
 Compressibility Index: 
Compressibility index is a measure of flow rate of powder and measure of relative 
importance of inter particulate interactions. The compressibility index of the granules was 
determined by the Carr’s compressibility index. 
Carr’s compressibility index (%) = [(TBD – LBD) × 100]/ TBD 
Table No. : 8.2 Relationship between % Compressibility and flowability: 
%compressibility Flowability 
5-15 Excellent 
12-16 Good 
18-21 Fair passable 
23-35 Poor 
 
Hausner ratio: 
            Hausner ratio is an indirect index of ease of powder flow. It was calculated by the 
following formula,  
                                             Hausner ratio = Pt/Pb 
                                Where, Pt = tapped density,    
                                            Pb = bulk density 
            Lower Hausner ratio (< 1.25) indicates better flow properties than higher ones (> 1.25). 
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8.2)  Post-compression assessment of Oro-dispersible tablet
(7)
:- 
Tablets were evaluated as per pharmacopoeial specifications. 
Weight variation: 
Twenty tablets were randomly selected from each batch and individually weighed. The 
average weight and standard deviation of 20 tablets was calculated. The batch passes the test for 
weight variation test if not more than two of the individual tablet weight deviates from the 
average weight by more than the percentage shown in officials and none deviate by more than 
twice the percentage shown as, 
Table No.8.3 : Weight variation tolerances for uncoated tablets 
 
 
Hardness: 
For each formulation, the hardness of 6 tablets was determined using the Monsanto 
hardness tester (Cadmach, Ahmedabad, India). Tablet was kept diagonally between the two 
plungers and a pressure was applied to it until the tablet broke down into two parts completely 
and the reading on the scale was noted down in kg/cm
2
. 
Friability: 
Roche friabilator (ElectrolabFriabilator – USP, Model No. EF-1W) was used to test the 
percent friability of the tablets. The tablets should be carefully dedusted prior to testing. Tablets 
were placed in drum, which was then rotated for 100 revolutions. After that tablets were 
Average weight of tablet (in mg) 
% Deviation 
As per USP-30/NF-25 As per IP-2007 
130 or less 80 or less 10 
From 130 through 324 80 mg < x < 250 mg 7.5 
more than 324 250 mg or more 5 
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removed and reweighed. The weight lost should not exceed the limit 1.0%. The percentage 
friability was measured using the formula, 
 
% F = [1 - (W/ W0)] × 100 
                                            Where, % F = friability in percentage 
                                                          W0 = Initial weight of tablet 
                                                           W = Weight of tablets after revolution. 
Thickness: 
The thickness of the tablets was determined using a digital calliper (ASAHI, India). Five 
tablets from the each batch were used and average values and SDs were calculated. 
      Wetting time: 
                           A piece of tissue paper folded double was placed in a Petri dish containing 6 ml 
of water .the tablet was placed on the paper, and time for the complete wetting of the tablet was 
measured in seconds. The method was slightly modified by maintaining water at 37
0
c.Wetting 
time corresponding to the time taken for the tablet to disintegrate when kept motionless on the 
Petri dish. 
              
                                    Fig no. 8.1 observation of wetting time 
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Tensile strength:  
The tensile strength (T) of the tablets was calculated using the formula,  
                                                  T≤2f/∏dt       
Where, 
                F≤ Crushing strength of the tablets 
                D≤ Diameter of the tablets 
                T≤ Thickness of the tablets 
Water absorption ratio: 
                        A piece of tissue paper folded twice was placed in a small Petri dish (7.5cm) 
containing 7 ml water.  Tablet was put on the tissue paper & allow to wet completely. The wetted 
tablet was then weighed.  
The water absorption ratio, R, was determined using following equation. 
    R = 100× (Wa-Wb)/Wb   Where,  
                                                     Wa = weight of a tablet after absorption 
                                                     Wb = weight of a tablet before absorption 
Three trials for each were performed, 
                                    
                 Fig No 8.2: method for measuring the wetting time and water absorption ratio. 
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Estimation of drug content 
(10) 
The drug content uniformity was calculated on all the formulations of dispersible tablets. 
The study was carried out in triplicate. Table No.10.16  shows the results of the drug content 
uniformity in each formulation with S.D. values.  
These values are found satisfactory, which ensures dosage uniformity and meets with 
requirements of USP (± 10% deviation). 
 
Disintegration Time: 
           In vitro disintegration time of tablets from each formulation was determined by 
using the Digital Tablet Disintegration Apparatus. In vitro disintegration test was carried out at 
37±2
o
C in 900 ml distilled water. 
 In-vitro Dissolution studies
(8)
: 
                  In-vitro dissolution studies for all the fabricated tablets of Cinnarizine were carried 
out using USP apparatus type II at 50 rpm. The dissolution medium used was 0.1N HCL (900ml) 
maintained at 37 ± 0.5
o
C.  
              Aliquots of dissolution media were withdrawn (10ml) at different intervals and content 
of Cinnarizine was measured by determining absorbance at 292 nm. 10ml aliquot was withdrawn 
at the 0min, 30sec,1min,1.30min.........to be continued at the 30sec intervals and filter by 
whatmann filter paper. And analyzed at 292nm using-visible spectrophotometer (ELICO SL 164 
Double beam UV visible spectrophotometer). 
            An equal volume of fresh medium, which was pre-warmed at 37
0
c replaced in to the 
dissolution medium after each sampling to maintain the constant volume throughout the test. The 
dissolution experiment were conducted in triplicate. And the same procedure is followed using 
dissolution medium pH 6.8 buffer. 
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                                      Fig no. 8.3 dissolution apparatus 
 
 Stability studies of the tablet
 (9)
: 
                        Stability of a formulation can be defined as the time from date on manufacture of 
the formulation until its chemical or biological activity is not less than a pre-determined level of 
labelled potency and its physical characteristic have not changed the appreciably or 
deleteriously. Formulation and the development of a pharmaceutical product are not complete 
without proper stability analysis, carried out on it to assess the physical and chemical stability 
and the safety. The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of environment 
factor such as temperature, humidity and light enabling recommended storage condition, re-test 
periods and shelf lives. 
                     Generally the observation of the rate at which the product degrades under normal 
room temperature requires a long time. To avoid the undesirable delay, the principle of 
accelerated stability studies is adopted. 
                    The international conference on harmonization (ICH) guideline titled “stability 
testing of the new drug substance and product” (QIA) describes the stability test requirements for 
drug registrations application in the European Union, Japan and United States of America. ICH 
specifies the length of study and storage conditions.   
 Long term testing: 25
0
c ± 2
0
c/60% RH ± 5% for 12 months. 
 Accelerated testing: 40
0
c ± 2
0
c/ 75 % RH ± 5% for 6 months. 
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Method: 
               The selected formulation were packed in tightly closed container were plugged with the 
cotton and capped they were then stored at 40
0
c  ± 2
0
c/ 75 % RH  ± 5% for 3 months in humidity 
chamber (Thermolab Mumbai) and valuate for their physical appearance and drug solution were 
further scanned to observe any possible spectral changes T80% was calculated by using 
dissolution studies. 
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9.1 Formulation Design: 
i) Selection of superdisintegrant 
 A disintegrant is included in the formulation to ensure that the tablet, when in the contact 
with a liquid, breaks up into small fragments, which promotes rapid drug dissolution. Ideally, the 
tablet should break up into individual drug particles in order to obtain the largest possible 
effective surface area during dissolution.  
The disintegration process for tablet occurs into two steps. First, the liquid wets the solid 
and penetrates the pores of the tablet. Thereafter, the tablet breaks into smaller fragments. A 
disaggregation directly into primary powder particles will set up the conditions for the possible 
dissolution of the drug. 
          The disintegration times of these tablets depend largely on the size of dosage form and 
hardness parameter. The basic approach used in the development of the Oral dispersible  tablet is 
the use of superdisintegrants. 
 
Preliminary study was carried out for screening of three superdisintegrants namely, 
1) Crospovidone 
2) Croscarmellose 
3) Cellactose80 
         
                            Drug, mannitol, aspartame, magnesium stearate, microcrystalline cellulose and 
various concentrations of superdisintegrants were taken and compressed by direct compression 
method. The weight of tablet in all batches were kept the constant. All the batches of tablets were 
prepared by Direct compression method using 21- station rotary tablet machine (Rimek 
machineries Ltd).Effect of disintegrating agents and their concentrations on various tablets 
properties and in-vitro dissolution characteristics were studied and discussed.  
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                         Table 9.1 Formulation design of tablets    (All conc. are in mg)  
Sr.no Ingredients  Af1 Af2 Af3 Bf1 Bf2 Bf3 Cf1 Cf2 Cf3 
1. Cinnarizine 25 25 25 25 25 25 25 25 25 
2. Crospovidone 10 15 20 _ _ _ _ _ _ 
3. Croscarmellose _ _ _ 10 15 20 _ _ _ 
4. Cellactose80 _ _ _ _ _ _ 10 15 20 
5. Lactose 20 20 20 20 20 20 20 20 20 
6. Microcrystalline 
cellulose 
35 30 25 35 30 25 35 30 25 
7. Magnesium 
stearate 
5 5 5 5 5 5 5 5 5 
8. Sodium lauryl 
sulphate 
2 2 2 2 2 2 2 2 2 
9. Menthol 2 2 2 2 2 2 2 2 2 
10 Aspartame 10 10 10 10 10 10 10 10 10 
11. Mannitol  91 91 91 91 91 91 91 91 91 
 Total  200 200 200 200 200 200 200 200 200 
 
ii) Preparation of powder blends of Drug and Excipients:
 
                              Oral dispersible tablets of Cinnarizine was prepared  using direct compression  
method  after incorporating different superdisintegrants such as, Croscarmellose sodium (Ac-Di-
Sol) and  Cellactose80  in different concentrations.  
                            Avicel PH 101 (MCC), Mannitol as directly compressible diluents, Ac-Di-Sol, 
crospovidone and Cellactose80 were tried as superdisintegrants. the efficacy of these super  
disintegrants in any fast dissolving dosage forms depends upon its selection,  concentration used, 
method of incorporation and steps used for preparation and / phycochemical characteristics of 
the formulation.  
              All the ingredients were passed through 60 mesh sieve separately and then 
ingredients were weighed and mixed in a geometrical order. First MCC, Mannitol and 
superdisintegrants were weighted and mixed together. Then drug and aspartame complex mixer 
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is added in first mixer and finally magnesium stearate was added and mixed for 10-15min. The 
tablets were then compressed using 12 mm size punches to get a tablet of 200 mg.  
        Before tablet preparation, the mixture blend of all the formulation were subjected for 
compatibility studies I.R. and pre-compressible parameters like angle of repose, bulk density, 
tapped density, compressibility index and Hauser’s ratio.   
                 The Oro-dispersible tablets prepared subjected to post compression parameters like 
hardness, friability, weight variation, wetting time, water absorption ratio, in-vitro dissolution 
and in-vitro disintegration. Tablet compression was carried out in rotary compression machine. 
Compression force was kept constant throughout the study. Compression was carried out using 
7.5 mm concave faced punches. Multiple Punch Single Rotary, Rimek Tablet  Compression 
Machine according to the 1, 2, 3, 4, 5,......... a total number of nine formulations were prepared 
and weight of all tablets kept constant.i.e 200 mg. 
 
PREPARATION OF CINNARIZINE ORAL DISPERSIBLE TABLETS BY DIRECT 
COMPRESSION :  
                  The tablets were prepared by direct compression method. Weigh of all ingradients as 
formula then mix well. Taken well mixed all ingredients, then that blend was punched at low 
pressure in 12mm punch on 21 station “B” tooling rotator tablet punching machine (RIMEK 
MUMBAI). The tablets are forms.  
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9. RESULTS AND DISCUSSION 
                          The present work was aimed to find out the effects of various superdisintegrants 
on the dissolution profile and various properties of oral dispersible tablets of Cinnarizine. 
9.1  PREFORMULATION STUDIES 
a) Identification test for Cinnarizine. 
i. Melting point: The melting point of the Cinnarizine was found to be 1180C-1200C, which 
complies with melting point reported ones. 
ii. Infrared absorption spectrophotometry: All the prominent and primary peaks were 
observed in FTIR spectrum of Cinnarizine (Fig. 10.1) and match with the reference 
spectrum. 
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                                               Figure 10.1: FTIR Spectrum of drug sample. 
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9.2.)  Standard calibration curve of Cinnarizine in hydrochloric acid buffer pH 1.2: 
i) Qualitative identification: 30 µg/ml solution of Cinnarizine was prepared in HCl 
buffer pH 1.2 and was subjected to scanning under UV visible spectrophotometer, 
between 200-400 nm. The λmax was found to be at 254 nm.                                                                                                                                                                                                                                                                                     
 
ii) Preparation of standard calibration curve in HCl buffer pH 1.2:  
                     Standard calibration curve was prepared for concentration of 5µg/ml to 25µg/ml at 
254 nm. The graph of absorbance v/s concentration was plotted and data were subjected to linear 
regression analysis. The standard calibration curve of drug in HCl buffer pH 1.2 was as depicted 
in Figure 9.2 The data had correlation coefficient of 0.999  and equation of regressed line is, 
y=0.041X+0.005 
 
Table No. 10.1: Absorbance values for standard calibration curve of Cinnarizine in hydrochloric 
acid buffer pH 1.2 
 
 
 
 
 
 
 
 
 
Sr. No. 
Concentration 
(μg/ml) 
Absorbance 
 
1 0 
0 
2 5 
0.201 
3 10 
0.410 
4 15 
0.630 
5 20 
0.810 
6 25 
1.054 
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                           Graph 10.1: Standard calibration curve of Cinnarizine in pH 1.2 buffer 
The calibration curve for Cinnarizine in pH 1.2 buffers in the concentration range of 
5μg/ml to 25μg/ml was a straight line. The absorbance increased with the increase in 
concentration. Thus the standard curve followed the Beer-Lambert’s Law. 
9.3) Standard calibration curve of Cinnarizine in phosphate buffer pH 6.8: 
a) Qualitative identification: 30 µg/ml solution of Cinnarizine was prepared in phosphate 
buffer pH 6.8 and was subjected to scanning under UV visible spectrophotometer, between 200-
400 nm. The λmax was found to be at 254 nm. (Figure 9.5). 
              
                As described earlier in section 3.5.5 standard calibration curve was prepared for 
concentration of 5µg/ml to 25µg/ml at 254 nm. The graph of absorbance v/s concentration was 
plotted and data were subjected to linear regression analysis. The standard calibration curve of 
drug in phosphate buffer pH 6.8 was as depicted in Figure 9.5 The data of absorbance is as 
shown in Table 9.2 The data had correlation coefficient of 0.998 and equation of regressed line 
is,                                                              
                                                 y = 0.042x - 0.016 
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Table No. 10.2: Absorbance values for standard calibration curve of Cinnarizine in phosphate                            
buffer pH 6.8 
 
 
 
    
 
 
 
 
 
                    
                        
                     Graph 10.2: Standard Calibration curve of Cinnarizine in pH6.8 buffer 
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Sr. No. 
Concentration 
(μg/ml) 
Absorbance 
1 0 0 
2 5 0.20 
3 10 0.400 
4 15 0.555 
5 20 0.850 
6 25 1.051 
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Colour, odour, taste and appearance: 
                                        Table . 10.3 Parameter Drug Powder 
Sr.no Parameter  Drug  
1 Colour  White  
2 Odour  Odourless  
3 Taste  Tasteless  
4 Appearance  Amorphous powder 
 
Drug and Excipients compatibility studies: 
                  Infrared spectra matching approach was used for the detection of any possible 
chemical reaction between the drug and all Excipients. About 100 mg of this mixture was 
compressed to from a transparent pellet using a hydraulic press at 10 tons pressure. It was 
scanned from 4000 to400cm-1 in a Perkin Elmer FTIR Spectrophotometer.  The IR spectrum 
of the physical mixture was done to detect any appearance or disappearance of peaks. 
      The compatibility between the drug and excipients were evaluated using FTIR matching 
method. The IR spectra of physical mixture are shown in figure. 
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                                  Figure no.10.2 FTIR spectrum of Physical mixture 
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 Cinnarizine (IR Spectra): 
                     Cinnarizine shows the C=C aromatic stretching at 1594.22 & 1491.02cm
-1
, N-H at 
3416.05cm
-1, 
C-H at 3024.56cm
-1
, CH3 bending at 1446.66 & 1363.72cm
1
, CH2 bending at 
1446.66cm
-1
, Aromatic stretching at 3166.26cm
-1
, Aromatic stretching out of plane 862.21cm
-1
, 
C=C alkaane 1594.22cm
-1 
Drug and physical mixture (IR spectra): 
Cinnarizine with physical mixture shows C=C at 1575 &1488.13cm
-1
, N-H at 3392.90cm
-1
, C-H 
at 3024.56cm
-1
, CH3 bending at 1428.34 & 1361.79cm
-1
, CH2 bending at 1428.34cm
-1
, Aromatic 
stretching at 2976.26cm
-1
, Aromatic stretching out of plane at 882.46cm
-1
, C=C alkane at 
1536.35cm
-1
, C=O at 1712.85cm
-1
, O-H at 3416.05cm
-1 
 
Pre-compression study of tablet blend: 
                 Nine formulations were prepared by using 5%, 7.5%, 10% concentration of 
superdisintegration of superdisintegrants croscarmellose, crospovidone and cellactose80. For 
each desined formulation, powder mixed blend of drug and excipients was prepared and 
evaluated for various parameters as follows. 
 
Angle of Repose (θ):The and angle of repose of various powder mixed blend, prepared with 
different superdisintegrants, was measured by the cylinder method. Angle of repose was found in 
the range  from 27.25 to 33.27 the  good flowability  of  powder  blend was also evidenced  with 
angle of repose which is indicated a good flowability. The result are given in table no 10.4 
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                                                        Table no 10.4 
 
 
Bulk density:  The bulk density of various powder mixed blends. Prepared with the different 
superdisintegrants was measured by graduated cylinder. The bulk density was found in the range 
from 0.5 to 0.526 The result are presented in Table no 10.5 
                                                                 Table no.10.5. 
Batch code Bulk density (gm/cm
3
) 
Af1 0.5 
Af2 0.5263 
Af3 0.5 
Bf1 0.5 
Bf2 0.520 
Bf3 0.526 
Cf1 0.520 
Cf2 0.519 
Cf3 0.524 
 
 
Batch code Angle of repose (θ) 
Af1 30.96 
Af2 31.21 
Af3 30.60 
Bf1 31.60 
Bf2 32.46 
Bf3 33.27 
Cf1 30.45 
Cf2 27.25 
Cf3 28.51 
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Tapped density: The tapped density of various powder mixed blends prepared with different 
superdisintegrants, was measured by the measuring cylinder. The tapped density was found in 
the range from 0.602 to 0.627. The result are given in Table no. 10.6 
                                                                 Table no.10.6. 
Batch code Tapped density 
(gm/cm
3
) 
Af1 0.602 
Af2 0.625 
Af3 0.625 
Bf1 0.602 
Bf2 0.617 
Bf3 0.609 
Cf1 0.621 
Cf2 0.627 
Cf3 0.628 
 
Compressibility Index: The compressibility index of various powder mixed blends prepared 
with the different superdisintegrants using bulk density and tapped density data, compressibility 
index was calculated. It was found in the range 15.02 to 17.22 The results are given in table 
no.10.7                                                     Table no.10.7 
Batch code Compressibility Index(%) 
Af1 16.94 
Af2 15.79 
Af3 15.79 
Bf1 16.94 
Bf2 15.72 
Bf3 15.02 
Cf1 16.26 
Cf2 17.22 
Cf3 16.59 
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Hausner ratio: The Hausner ratio of various powder mixed blends prepared with different 
superdisintegrants, it was calculated by the using bulk density and tapped density data. It was 
found in the range of 1.17 to 1.25. The results are given in Table no.10.8                                                                                
                                                              Table no.10.8 
Batch code Hausner ratio 
Af1 1.204 
Af2 1.188 
Af3 1.25 
Bf1 1.204 
Bf2 1.186 
Bf3 1.17 
Cf1 1.19 
Cf2 1.20 
Cf3 1.199 
 
Evaluation of oral dispersible tablet of Cinnarizine: 
                         In this work for the ease of analysis and to study the impact of various 
superdisintegrants on enhancing the dissolution of Cinnarizine. The experiment was design with 
seven formulations which were categorize into three group based on the concentration of 
superdisintegrants. 
 
Weight variation: Tablets were prepared using direct compression technique. Since the material 
was free flowing, tablets were obtained of uniforms weight due to uniform die fill. The tablets 
were obtained in the range with acceptable weight variations as per pharmacopoeia specifications 
less than 7.5%. The results are given in table no 10.9 
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                                                 Table no.10.9 
Batch code Weight (mg) ± S.D 
Af1 199.985 ± 
Af2 200.825± 
Af3 199.765± 
Bf1 201.01± 
Bf2 200.03± 
Bf3 200.81± 
Cf1 201.3± 
Cf2 202.61± 
Cf3 199.12± 
 
 
Thickness uniformity: Tablets were evaluated by  using the verniercaliper. The thickness of 
tablets was found to be exact .3.5 uniform thickness was obtained due to uniform die fill. The 
result are given in table no 10.10                           
                                                               Tablet no.10.10 
Batch code Thickness (mm) 
Af1 3.571 
Af2 3.552 
Af3 3.558 
Bf1 3.573 
Bf2 3.568 
Bf3 3.568 
Cf1 3.571 
Cf2 3.574 
Cf3 3.60 
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Hardness:  Tablets were evaluated by using hardness tester. Hardness of the tablets was found in 
the range 1.91 to 2.02. The result are given in table no 10.11                                    
                                                                 Table no.10.11. 
Batch code Hardness (kg/cm2) 
Af1 1.98 
Af2 1.98 
Af3 2.02 
Bf1 1.95 
Bf2 1.96 
Bf3 2.0 
Cf1 1.91 
Cf2 2.02 
Cf3 1.967 
 
Friability:  Tablets were evaluated by using the Roche Friabilator and Friability of tablets was 
observed in acceptable range 0.48 to 0.81 (Less than 1%).The results are given in table no 10.12 
                                                                   Table no 10.12. 
Batch code Friability (%) 
Af1 0.650 
Af2 0.771 
Af3 0.589 
Bf1 0.7181 
Bf2 0.81 
Bf3 0.70 
Cf1 0.48 
Cf2 0.53 
Cf3 0.79 
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Tensile strength: The tensile strength of tablet was calculated by using the crushing strength, 
diameter and thickness of the tablets. It was found in the range 4.09 to 5.91  The result are given 
in table no.10.13                                       Table no.10.13. 
Batch code Tensile strength 
(kg/cm
2
) 
Af1 4.36 
Af2 4.33 
Af3 4.09 
Bf1 5.73 
Bf2 5.91 
Bf3 5.37 
Cf1 5.37 
Cf2 4.99 
Cf3 4.55 
 
Disintegration time: Tablets were evaluated for disintegration time in the disintegration test 
apparatus (I.P)  The disintegration time was found in the range ..25 to 35 for all the batches. The 
batch AF3 showed the fastest disintegration. The result are given in Table no.10.14  
                                                                 Table no.10.14. 
Batch code Disintegration time 
(sec) 
Af1 27 
Af2 26 
Af3 25 
Bf1 32 
Bf2 33 
Bf3 35 
Cf1 30 
Cf2 32 
Cf3 31 
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                     Graph No. 10.3  Disintegration time. 
  Water absorption ratio: A piece of tissue paper folded twice was  placed in a small petri-dish 
(6.5cm) containing 6ml of water, a tablet was placed on paper and the time for complete wetting 
was measured the wetted tablet was then weighed and the water absorption ratio was calculated 
for each batch. The ratio was calculated for each batch. The ratios are given in the table no.10.15                                             
                                                                 Table no.10.15. 
Batch code Water absorption ratio 
±S.D 
Af1 82.80±5.76 
Af2 83.09±2.45 
Af3 60.62± 7.90 
Bf1 90.03±6.04 
Bf2 67.76± 3.64 
Bf3 97.08±1.96 
Cf1 63.18± 4.86 
Cf2 67.76± 3.64 
Cf3 60.62± 7.91 
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Estimation of drug content : 
The drug content uniformity was calculated on all the formulations of dispersible tablets. 
The study was carried out in triplicate. Table No.10.16 shows the results of the drug content 
uniformity in each formulation with S.D. values.  
These values are found satisfactory, which ensures dosage uniformity and meets with 
requirements of USP (± 10% deviation). 
. 
                                                                Table no.10.16 
Sr.no Batch code Content uniformity 
(%) 
1 Af1 95.76 
2 Af2 96.06 
3 Af3 99.96 
4 Bf1 94.60 
5 Bf2 94.63 
6 Bf3 95.32 
7 Cf1 92.96 
8 Cf2 93.59 
9 Cf3 94.07 
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In-vitro release studies: 
                         The Comparative analysis of each formulation was based on in vitro kinetic 
parameters, which elucidated the release profile. The time taken for 80% drug release was taken 
as a response for comparative interpretation of superdisintegrants. The in-vitro drug release of  
tablets of Cinnarizine for all formulation are given as follows. 
 
In vitro drug release studies details: 
Apparatus used                         : USP XXIII dissolution test apparatus 
Dissolution medium                  : 0.1N HCL  
Dissolution medium volume     : 900 ml 
Temperature                              : 37±0.5ºC 
Speed of basket paddle             : 50 rpm 
Sampling intervals                    : 0.30 Sec 
Sample withdrawn                    : 10 ml 
Absorbance measured               : 254 nm 
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In-vitro release studies of batch AF1in 0.1N HCL 
                                                             Table no.10.17 
Sr.no Time (min) Percent drug 
release 
1 0 1.86 
2 1 12.08 
3 2 45.10 
4 3 63.76 
5 4 65.76 
6 5 69.91 
7 6 75.18 
8 7 78.69 
9 8 90.54 
10 9 94.5 
11 10 99.87 
 
                                                                   
                          Graph. No 10.4 In-vitro release studies of batch AF1in 0.1N HCL 
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In-vitro release studies of batch AF2 in 0.1N HCL 
                                                        Table no.10.18 
Sr.no Time (min) Percent drug 
release 
1 0 4.0 
2 1 10.17 
3 2 22.71 
4 3 67.06 
5 4 73.53 
6 5 77.59 
7 6 85.82 
8 7 91.21 
9 8 97.13 
10 9 99.63 
 
                       
                      Graph. No 10.5 In-vitro release studies of batch AF2 in 0.1N HCL 
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In-vitro release studies of batch AF3 in 0.1N HCL 
                                                          Table no.10.19 
Sr.no Time (min) Percent drug 
release 
1 0 2.7 
2 1 27.98 
3 2 45.87 
4 3 56.19 
5 4 57.52 
6 5 78.69 
7 6 88.02 
8 7 89.78 
9 8 99.32 
 
 
                   
                       Graph  No 10.6 In-vitro release studies of batch AF3 in 0.1N HCL 
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In-vitro release studies of batch BF1 in 0.1N HCL 
                                                        Table no.10.20 
Sr.no Time (min) Percent drug 
release(%) 
1 0 1.09 
2 1 12.51 
3 2 20.96 
4 3 23.81 
5 4 32.15 
6 5 46.31 
7 6 55.09 
8 7 68.81 
9 8 77.59 
10 9 91.76 
11 10 96.25 
12 11 99.87 
 
                   
                       Graph  No 10.7 In-vitro release studies of batch BF1 in 0.1N HCL 
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In-vitro release studies of batch  BF2in 0.1N HCL 
                                                          Table no.10.21. 
Sr.no Time (min) Percent drug 
release(%) 
1 0 1.6 
2 1 13.60 
3 2 35.34 
4 3 44.56 
5 4 52.80 
6 5 55.09 
7 6 58.60 
8 7 64.42 
9 8 67.93 
10 9 88.46 
11 10 94.39 
12 11 99.65 
 
                   
                           Graph No 10.8 In-vitro release studies of batch BF2in 0.1N HCL 
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In-vitro release studies of batch BF3 in 0.1N HCL 
                                                          Table no.10.22 
Sr.no Time (min) Percent drug 
release 
1 0 1.2 
2 1 17.12 
3 2 22.39 
4 3 33.80 
5 4 39.62 
6 5 43.46 
7 6 58.39 
8 7 64.42 
9 8 67.5 
10 9 79.79 
11 10 87.37 
12 11 88.46 
13 12 99.43 
 
                   
                        Graph No 10.9  In-vitro release studies of batch BF3 in 0.1N HCL 
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In-vitro release studies of batchCF1 in 0.1N HCL 
                                                         Table no.10.23 
Sr.no Time (min) Percent drug 
release 
1 0 0 
2 1 11.74 
3 2 21.51 
4 3 25.46 
5 4 32.70 
6 5 44.56 
7 6 52.35 
8 7 67.5 
9 8 72.10 
10 9 77.16 
11 10 87.47 
12 11 91.86 
13 12 98.01 
14 13 99.98 
 
                      
                          Graph No 10.10  In-vitro release studies of batch CF1 in 0.1N HCL 
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In-vitro release studies of batch CF2 in 0.1N HCL 
                                                        Table no.10.24 
Sr.no Time (min) Percent drug 
release 
1 0 0 
2 1 13.93 
3 2 22.39 
4 3 25.46 
5 4 33.58 
6 5 44.35 
7 6 46.86 
8 7 55.53 
9 8 64.97 
10 9 86.15 
11 10 91.75 
12 11 98.45 
13 12 99.98 
 
                 
                       Graph No 10.11  In-vitro release studies of batch CF2in 0.1N HCL 
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In-vitro release studies of batch CF3 in 0.1N HCL 
                                                         Table no.10.25 
Sr.no Time (min) Percent drug 
release 
1 0 1.86 
2 1 12.29 
3 2 20.63 
4 3 34.57 
5 4 38.63 
6 5 43.46 
7 6 57.29 
8 7 67.60 
9 8 79.68 
10 9 89.12 
11 10 95.38 
12 11 97.13 
13 12 99.21 
                       
                       
                     
                        Graph No 10.12  In-vitro release studies of batch CF3 in 0.1N HCL 
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COMPARATIVE IN VITRO DRUG RELEASE PROFILE OF ORAL DISPERSIBLE 
TABLET OF CINNARIZINE IN 0.1N HCL 
                                                     TABLE NO.10.26 
 
                            Form the above observation we can conclude that, as concentration of 
crospovidone, croscarmellose and cellactose80 increase the disintegration time also increase. But 
the superdisintegrant crospovidone gives the minimum disintegrating time as compare to 
croscarmellose or cellactose80. In the batch of crospovidone gives minimum disintegrating time 
i.e 8 mins and at the concentration of 10% of crospovidone. And the batch of croscarmellose and 
cellactose80 (at the same conc. Of superdisintegration i.e 10%) gives the disintegration time in 
the range of 11-12 min and 12-13 min respectively.  
Sr. 
no 
Time 
(min.) 
Percent drug release 
AF1 AF2 AF3 BF1 BF2 BF3 CF1 CF2 CF3 
1 0 1.86 4.0 2.7 1.09 1.6 1.2 0 0 1.86 
2 1 12.08 10.17 27.98 12.51 13.60 17.12 11.74 13.93 12.29 
3 2 45.10 22.71 45.87 20.96 35.34 22.39 21.51 22.46 20.63 
4 3 63.76 67.06 56.19 23.81 44.56 33.80 25.46 25.46 34.57 
5 4 65.76 73.53 57.52 32.15 52.80 39.62 32.70 33.58 38.63 
6 5 69.91 77.59 78.69 46.31 55.09 43.46 44.56 44.35 43.46 
7 6 75.18 85.82 88.02 55.09 58..60 58.39 52.35 46.86 57.29 
8 7 78.69 91.21 89.78 68.81 64.42 64.42 67.5 55.53 67.60 
9 8 90.54 97.13 99.32 77.59 67.93 67.5 72.10 64.97 79.68 
10 9 94.5 99.63  91.76 88.46 79.79 77.16 86.15 89.12 
11 10 99.87   96.25 94.39 87.37 87.47 91.75 95.38 
12 11    99.87 99.65 88.46 91.86 98.45 97.13 
13 12      99.43 98.01 99.98 99.21 
14 13       99.98   
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 Graph No 10.13  COMPARATIVE IN VITRO DRUG RELEASE PROFILE  OF               
ORAL DISPERSIBLE TABLET OF CINNARIZINE IN 0.1N HCL 
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STABILITY STUDIES OF CINNARIZINE TABLETS 
Aging studies of formulation of Oral dispersible tablets of Cinnarizine 
                        
                     40
0
c ± 2
0
c /75% RH ± 5% RH and At Room Temperature                                                 
                                           
                                         Table no.10.27.                                **≤ No Change   
Sr .no Evaluation Parameter Observation 
AF3 
1 Physical Appearance ** 
2 Weight Variation (mg) ** 
3 Hardness(kg/cm
2
) 2.00 
4 Friability (%) 0.70 
5 Drug content(mg/tablet) 98.96 
 
 
 
                                                                                               SUMMARY AND CONCLUSION 
 
DEPARTMENT OF PHARMACEUTICS, NCP, ERODE Page 96 
 
10) SUMMARY AND CONCLUSION 
 
10.1) Summary 
                              Cinnarizine is the antihistamine and widely used for treatment of nausea and 
vomiting due to motion sickness. Cinnarine act by interfering with signal transmission between 
vestibular tissue of inner ear and vomiting center of hypothalamus. 
                             Cinnarizine is rapidly absorbed and distributed in GI tract and has peak plasma 
concentration(1-3hrs) Cinnarizine undergoes number of biotransformation which include N-
oxidation, C-oxidation and oxidative cleavage of drug. It undergoes metabolism and has half 
life(3-4hrs) after oral admistration , so cinnarizine is effective in the control of antihistamine.                                
                         The aim of present work was to prepare a suitable oral dispersible tablet of 
Cinnarizine; twice a day Cinnarizine dosage form could reduce the dosing frequency and 
improve patient compliance 
                      Croscarmellose sodium, Crospovidone, Cellactose80 are used as superdisintegrants 
at minimum to maximum quantity which give better disintegration time with better releasing 
time was studied. The study gives the report that as we increase the concentration of 
superdisintegrating agents the disintegrating time and in-vitro drug release are also increases  
                             In the study all the formulation were subjected to physical parameters of 
tablets, like hardness, friability, weight variation, drug content of Cinnarizine. All the 
formulations resulted in acceptable limit except formulation AF3 and CF2 for hardness test 
marginally of the tablets. The final batch AF3 can be considered as optimized batch as it seems 
to be most promising formulation which gives the release up to 99.32% in 8 min.  
The drug-excipients interaction studies were carried out by FTIR. No significant interaction of 
drug with excipients was observed. During stability studies, no significant variation (1 to 3 %) in 
drug release was observed, indicating that formulation batch AF3 was stable over the chosen 
condition for 3 months. 
 
                      The optimized formulation batch AF3 showed better drug release profile with other 
formulations. 
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 Conclusion  
                      From the present study carried out on Cinnarizine oraldispersible tablet using by 
direct compression method, the following conclusion can be drawn. 
                     The total weight of optimized AF3 batch was 200 mg contained  Cinnarizine-
12.5%, crospovidone-10%, lactose-10%, microcrystalline cellulose-12.5%, magnesium stearate- 
2.5%, sodium lauryl sulphate-1%, menthol-1%, aspartame-5%, mannitol-45.5%   
                     The Prefromulation study gives the following information of optimize batch Angle 
of Repose-30.60 good to flow, Bulk density-0.5, Tapped density-0.625, Compressibility Index-
15.79 good to flow, Hausner ratio-1.25 
                      Post parameter evaluation of tablets shows the following readings are Weight 
variation-200.765±, Thickness uniformity-3.558, Hardness-2.02, Friability-0.589, Tensile 
strength-4.09, Disintegration time-25 sec, Water absorption ratio-, Content uniformity-99.96%, 
In-vitro release studies- in 9 min. The drug content is to be find out.  
                       A more the concentration of crospovidone is used for quick the disintegration and 
dissolution is to bee find out. The results give information that   Disintegration time in 25 sec. so 
crospovidone is the optimize batch on basis of disintegration time and in-vitro drug release. 
 
                      All the formulation batches fulfill the official limit for physical parameters like 
weight variation, hardness, friability and drug content uniformity. The in-vitro drug release 
studies indicated that the optimum release profile was found by the formulation batch AF3. By 
drug-excipients interaction studies, no significant interaction was found. Formulation batch AF3 
was found to be stable over the chosen temperature and humidity for 3 months. 
                      The optimized formulation of batch Af3 gave the best vitro release of 99.32% in 
8min in 0.1N HCL. The release of drug followed matrix diffusion mechanism. 
 
                       Our objective to fast dispersion of the tablet in oral cavity in quick time and has 
fulfilled and it definately gives the fast release action for its histamine activity. The oral 
dispersible tablets gives the quick onset of action as compared to convectional dosage form 
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leading to facilitation of its quick activity at the minimum time period. Hence it can be 
concluded that the formulation AF3 is a stable and effective for quick action. 
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